10-K
1
f10k2020_relmadatherapeutic.htm
ANNUAL REPORT
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-K
☒ ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☐ TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
Commission
file number: 000-55347
Relmada
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
45-5401931
(State
or other jurisdiction of
incorporation
or organization)
(I.R.S.
Employer
Identification
No.)
880
Third Avenue, 12 th Floor
New
York, NY 10022
(Address
of principal executive offices) (Zip Code)
(646)
876 3459
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Name
of Market Where Traded
Common Stock ($.001
par value)
The NASDAQ Capital
Market
Securities registered pursuant to section
12(g) of the Act:
None
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate
by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the
registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. ☐
Indicate by check mark whether the
registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes ☒ No ☐
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated
filer
☒
Smaller reporting company
☒
Emerging Growth Company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant’s most recently completed second fiscal quarter.
As of June 30, 2020 (the last business
day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s
common stock held by non-affiliates of the registrant was $694,982,670 based on the closing price as reported on the NASDAQ.
As of March 15, 2021, there were
16,745,930 shares of common stock, $0.001 par value per share, outstanding.
TABLE
OF CONTENTS
Item
Number and Caption
Page
Forward-Looking
Statements
ii
PART
I
1.
Business
1
1A.
Risk
Factors
12
1B.
Unresolved
Staff Comments
29
2.
Properties
29
3.
Legal
Proceedings
29
4.
Mine
Safety Disclosures
29
PART
II
5.
Market
for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
30
6.
Selected
Financial Data
7.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
31
7A.
Quantitative
and Qualitative Disclosures About Market Risk
36
8.
Financial
Statements and Supplementary Data
36
9.
Changes
in and Disagreements with Accountants on Accounting, and Financial Disclosure
36
9A.
Controls
and Procedures
36
9B.
Other
Information
37
PART
III
10.
Directors,
Executive Officers, and Corporate Governance
38
11.
Executive
Compensation
38
12.
Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
38
13.
Certain
Relationships and Related Transactions, and Director Independence
38
14.
Principal
Accounting Fees and Services
38
PART
IV
15.
Exhibits,
Financial Statement Schedules
39
i
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Annual Report on Form 10-K (this Report) contains forward looking statements that involve risks and uncertainties, principally
in the sections entitled “Description of Business,” “Risk Factors,” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations.” All statements other than statements of historical
fact contained in this Report, including statements regarding future events, our future financial performance, business strategy
and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking
statements by terminology including “anticipates,” “believes,” “can,” “continue,”
“could,” “estimates,” “expects,” “intends,” “may,” “plans,”
“potential,” “predicts,” “should,” or “will” or the negative of these terms or
other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis
for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties
and other factors, including the risks outlined under “Risk Factors” or elsewhere in this Report, which may cause
our or our industry’s actual results, levels of activity, performance or achievements to differ materially from those expressed
or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New
risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all
factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially
from those contained in any forward-looking statements. All forward-looking statements included in this document are based on
information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements.
You
should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Report on
Form-10-K. Before you invest in our securities, you should be aware that the occurrence of the events described in the section
entitled “Risk Factors” and elsewhere in this Report could negatively affect our business, operating results, financial
condition and stock price. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking
statements after the date of this Report on Form-10-K to conform our statements to actual results or changed expectations.
ii
PART
I
All
brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise,
references in this report to “Relmada,” the “Company,” “we,” “us,” and “our”
refer to Relmada Therapeutics, Inc., a Nevada corporation.
ITEM
1. BUSINESS
Business
Overview
Relmada Therapeutics, Inc. (Relmada, the
Company, we or us) (a Nevada corporation), is a clinical-stage biotechnology company focused on the development of esmethadone
(d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. esmethadone is a new chemical entity
(NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and
other disorders.
On
October 7, 2019, our application to list our common stock on the Nasdaq Capital Market was approved. On October 10, 2019,
our common stock began trading on Nasdaq under our existing symbol, “RLMD.”
On
December 19, 2019, the Board of Directors of the Company approved a change to its end of fiscal year from June 30 to December
31. The change in fiscal year became effective for the Company’s 2020 fiscal year, which began January 1, 2020 and ended
December 31, 2020. Accordingly the Company filed the transition report on Form 10-KT for the six-month period from July 1, 2019
through December 31, 2019 within the time period prescribed by the Securities and Exchange Commission.
Our lead product candidate, esmethadone,
is an NCE being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. We
have previously completed Phase 1 single and multiple ascending dose studies and on October 15, 2019 we reported top-line data
from study REL-1017-202. This was a double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety, tolerability
and efficacy of two oral doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with
major depressive disorder (MDD), who experienced an inadequate response to 1 to 3 adequate antidepressant treatments with an antidepressant
medication.
In
the REL-1017-202 study, 62 subjects, average age 49.2 years, with an average Hamilton Depression Rating Scale score of 25.3 and
an average Montgomery-Asberg Depression Rating Scale (MADRS) score of 34.0 (severe depression), were randomized. Other demographic
characteristics were balanced across all arms. After an initial screening period, subjects were randomized to one of three arms:
placebo, REL-1017 25 mg or REL-1017 50 mg, in addition to stable background antidepressant therapy. Subjects in the REL-1017 treatment
arms received one loading dose of either 75 mg (25 mg arm) or 100 mg (50 mg arm) of REL-1017. Subjects were treated inpatient
for 7 days and discharged home at Day 9. They returned for follow-up visits at Day 14 and Day 21. Efficacy was measured on Days
2, 4 and 7 in the dosing period and on Day 14, one week after treatment discontinuation. 61 subjects received all treatment doses
and were included in the per-protocol population (PPP) treatment analysis; 57 subjects completed all visits. All 62 randomized
subjects were part of the intention-to-treat (ITT) analysis. No differences were observed between the ITT and PPP analyses and
results.
Key
findings:
We
observed that subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement
on all efficacy measures tested as compared to subjects in the placebo group, including: the Montgomery-Asberg Depression Rating
Scale (MADRS); the Clinical Global Impression – Severity (CGI-S) scale; the Clinical Global Impression – Improvement
(CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ).
The
improvement on the MADRS appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after
treatment discontinuation, with P values< 0.03 and large effect sizes (a measure of quantifying the difference between two
groups), ranging from 0.7 to 1.0. Similar findings emerged from the CGI-S and CGI-I scales.
MADRS:
Analysis of Change from Baseline to Day 7 and to Day 14 ITT Population
Day
2
Day
4
Day
7
Day
14
LS
Means Difference
P-value
d
LS
Means Difference
P-value
d
LS
Means Difference
P-value
D
LS
Means Difference
P-value
d
REL-1017
25mg vs Placebo
-1.9
0.4340
0.3
-7.9
0.0087
0.9
-8.7
0.0122
0.8
-9.4
0.0103
0.9
REL-1017
50mg vs Placebo
-0.3
0.9092
0.0
-7.6
0.0096
0.8
-7.2
0.0308
0.7
-10.4
0.0039
1.0
1
LS
= Least Squares; d = Cohen’s effect size
The study also supported the favorable
tolerability profile of REL-1017, which was also observed in the Phase 1 studies. Subjects experienced mild and moderate adverse
events (AEs), and no serious adverse events, without significant differences between placebo and treatment groups. The AEs observed
in the Phase 2 clinical study were of the same nature as those observed in the Phase 1 clinical studies in esmethadone, and importantly
there was no evidence of either treatment induced psychotomimetic and dissociative AEs or withdrawal signs and symptoms upon treatment
discontinuation.
Phase
3 Program
On
December 20, 2020 we announced that the first patient had been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the
Company's lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder (MDD).
Key
points of the Phase 3 program agreed upon in discussions with FDA include:
● The
Phase 3 program will consist of two sister, two-arm, placebo-controlled clinical trials.
Each trial will be conducted in 55 clinical sites in the United States and will include
approximately 400 MDD patients with inadequate response to standard antidepressants
in their current depression episode. Patients will add either a 25 mg oral dose
of REL-1017 once per day or placebo to their ongoing antidepressant treatment.
● The
primary endpoint to be evaluated will be the change from baseline on the Montgomery and
Asberg Depression Rating Scale (MADRS) score at day-28 for REL-1017 compared to
placebo. Success on this endpoint with the collection of sufficient safety data
would support the use of REL-1017 for chronic treatment, if approved.
● The
change from baseline and the 7-day MADRS score will serve as a key secondary endpoint
and will provide data on the rapid onset of treatment effect; statistically significant
separation between REL-1017 and the control group was achieved by day 4 in the Phase
2 proof-of-principle trial completed in 2019.
● The
Company expects to initiate the second Phase 3 trial, RELIANCE II, in the first half
of 2021. Patients who complete RELIANCE I and RELIANCE II will be eligible to rollover
into the long-term, open-label study, which is also expected to include subjects who
had not previously participated in a REL-1017 clinical trial.
Key
Upcoming Anticipated Milestones
We
expect multiple key milestones over the next 12-18 months. These include:
● Start
of RELIANCE II, the second pivotal Phase 3 adjunctive MDD trial in the first half of 2021.
●
Start of Phase 2 monotherapy MDD trial in the first half of 2021.
●
Results of oxycodone human abuse potential study in the second quarter of 2021.
●
Results of IV ketamine human abuse potential study in the fourth quarter of 2021.
● Results
of RELIANCE I and RELIANCE II adjunctive MDD trials in the first half of 2022.
Our
Development Program
Esmethadone (d-Methadone, dextromethadone, REL-1017) as a
treatment for MDD
Background
In
2014, the National Institute of Mental Health (NIMH) estimated that 15.7 million adults aged 18 or older in the United States
had at least one major depressive episode in the past year. According to data from nationally representative surveys supported
by NIMH, only about half of Americans diagnosed with major depression in a given year receive treatment. Of those receiving treatment
with as many as four different standard antidepressants, 33% of drug-treated depression patients do not achieve adequate therapeutic
benefits according to the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial published in the American Journal
of Psychiatry.
In
addition to the high failure rate, only one of the marketed products for depression, esketamine (marketed by Johnson and Johnson
as Spravato), an in-clinic nasal spray treatment can demonstrate rapid antidepressant effects, while the other currently approved
products can take two to four weeks to show activity. The urgent need for improved, faster acting antidepressant treatments is
underscored by the fact that severe depression can be life-threatening, due to heightened risk of suicide.
2
Esmethadone Overview and Mechanism of Action
Esmethadone’s mechanism of action,
as a low affinity, non-competitive NMDA channel blocker or antagonist, is fundamentally differentiated from most currently FDA-approved
antidepressants, as well as all atypical antipsychotics used adjunctively with standard, FDA-approved antidepressants. Working
through the same brain mechanisms as ketamine and esketamine but potentially lacking its adverse side effects, esmethadone is being
developed as a rapidly acting, oral agent for the treatment of depression and potentially other CNS conditions.
In chemistry an enantiomer, also known
as an optical isomer, is one of two stereoisomers that are mirror images of each other that are non-superimposable (not identical),
much as one’s left and right hands are the same except for being reversed along one axis. A racemic compound, or racemate,
is one that has equal amounts of left- and right-handed enantiomers of a chiral molecule. For racemic drugs, often only one of
a drug’s enantiomers is responsible for the desired physiologic effects, while the other enantiomer is less active or inactive.
As a single isomer of racemic methadone,
esmethadone has been shown to possess NMDA antagonist properties with virtually no traditional opioid or ketamine-like adverse
events at the expected therapeutic doses. In contrast, racemic methadone is associated with common opioid side effects that include
anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhea, drowsiness, and others.
It has been shown that the left (levo) isomer, l-methadone, is largely responsible for methadone’s opioid activity, while
the right (dextro) isomer, esmethadone, at the currently therapeutic doses used in development is virtually inactive as an opioid
while maintaining affinity for the NMDA receptor.
NMDA receptors are present in many parts
of the CNS and play important roles in regulating neuronal activity and promoting synaptic plasticity in brain areas important
for cognitive functions such as executive function, learning and memory. Based on these premises, esmethadone could show benefits
in several different CNS indications.
Esmethadone (d-methadone, dextromethadone, REL-1017) in other
indications
In addition to developing esmethadone as
an adjunctive treatment of MDD, we are planning to evaluate the utility of esmethadone as a front line monotherapy treatment for
MDD.
Additionally, other indications that Relmada
may explore in the future, include, restless leg syndrome and other glutamatergic system activation related diseases.
Our Corporate History and Background
We are a clinical-stage, publicly traded
biotechnology company developing NCEs and novel versions of proven drug products that potentially address areas of high unmet medical
need in the treatment of depression and other CNS diseases.
Currently, none of our product candidates
have been approved for sale in the United States or elsewhere. We have no commercial products nor do we have a sales or marketing
infrastructure. In order to market and sell our prospective products we must conduct clinical trials on patients and obtain regulatory
approvals from appropriate regulatory agencies, like the FDA in the United States, and similar organizations elsewhere in the world.
We have not generated revenues and do not
anticipate generating revenues for the foreseeable future. We had net loss of approximately $59,456,400 for the year ended December
31, 2020, $8,196,500 for the six months ended December 31, 2019, and $17,318,100 for the year ended June 30, 2019, respectively.
At December 31, 2020, we have an accumulated deficit of approximately $179,315,300.
3
Business
Strategy
Our strategy is to leverage our considerable
industry experience, understanding of CNS markets and development expertise to identify, develop and commercialize product candidates
with significant market potential that can fulfill unmet medical needs in the treatment of CNS diseases. We have assembled a management
team along with both scientific, including recognized experts in the fields of depression, and business advisors with significant
industry and regulatory experience to lead and execute the development and commercialization of esmethadone.
We plan to further develop esmethadone
as our priority program. As the drug esmethadone is an NCE, the regulatory pathway, under the Food and Drug Administration Amendment
Act Section 505(u) provision, required to support an NDA submission will consist of conducting a full clinical development program.
We plan to also generate intellectual property (IP) that will further protect our products from competition. We will continue to
prioritize our product development activities after taking into account the resources we have available, market dynamics and potential
for adding value.
Market
Opportunity
We
believe that the market for addressing areas of high unmet medical need in the treatment of CNS diseases will continue to be large
for the foreseeable future and that it will represent a sizable revenue opportunity for us. For example, the World Health Organization
(WHO) has estimated that CNS diseases affect nearly 2 billion people globally, making up approximately 40% of total disease burden
(based on disability adjusted life years), compared with 13% for cancer and 12% for cardiovascular disease.
The depression treatment market is segmented
on the basis of antidepressants drugs, devices, and therapies. Antidepressants are the largest and most popular market segment.
The antidepressants segment consists of large pharmaceutical and generic companies, such as Eli Lilly, Pfizer, GlaxoSmithKline,
Allergan, Sage Therapeutics and Johnson & Johnson. Some of the notable drugs produced by these companies are Cymbalta ®
(Eli Lilly), Effexor ® (Pfizer), Pristiq ® (Pfizer), Zulresso (Sage) and Spravato (Johnson & Johnson).
Intellectual
Property Portfolio and Market Exclusivity
We have over 50 issued patents and pending
patent applications related to REL-1017 for multiple uses, including psychological and neurological conditions. We have also secured
an Orphan Drug Designation from the FDA for d-methadone for “the treatment of postherpetic neuralgia’, which, if pursed
and upon potential NDA approval, would carry 7-year FDA Orphan Drug marketing exclusivity. In the European Union, some of our actual
and prospective products may be eligible up to 10 years of market exclusivity, which includes 8 years data exclusivity and 2 years
market exclusivity. In addition to any granted patents, REL-1017 will be eligible for market exclusivity to run concurrently with
the term of the patent for 5 years in the U.S. (Hatch Waxman Act) plus additional 6 month of pediatric exclusivity and up to 10
years of in the E.U. We believe an extensive intellectual property estate of US and foreign patents and applications, will protect
our technology and products once our patent applications for our products are approved.
Esmethadone License Agreement
As a result of a prior acquisition, the Company assumed an obligation
to pay third parties (Dr. Charles E. Inturrisi and Dr. Paolo Manfredi – see below): (A) royalty payments up to 2% on net
sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received
by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by
licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million,
for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial
sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of December 31,
2020, the Company has not generated any revenue related to this license agreement.
Inturrisi / Manfredi
In January 2018, we entered into an Intellectual
Property Assignment Agreement (the Assignment Agreement) and License Agreement (the License Agreement and together with the Assignment
Agreement, the Agreements) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the Licensor). Pursuant to the Agreements,
Relmada assigned its existing rights, including patents and patent applications, to esmethadone in the context of psychiatric use
(the Existing Invention) to Licensor. Licensor then granted Relmada under the License Agreement a perpetual, worldwide, and exclusive
license to commercialize the Existing Invention and certain further inventions regarding esmethadone. In consideration of the rights
granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally,
Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial
sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of
the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered
royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products
covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%,
and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.
4
The License Agreement includes standard
termination rights for Licensor in the event of our insolvency, challenge of the licensed patents and uncured material breach of
our obligations under the License Agreement. In addition, the License Agreement contains certain “Key Man” provisions
such that Licensor may terminate the License Agreement if we terminate the employment of our Chief Executive Officer Dr Sergio
Traversa for any reason other than for specified causes determined by a majority of our Board of Directors (including fraud, gross
negligence, unauthorized use of our confidential information, conduct including harassment or discrimination, breach of fiduciary
duty or uncured material breach), or if we (a) substantially modify Dr. Traversa’s job responsibilities or decision-making
rights in connection with the development and commercialization of esmethadone, (b) remove him from the role of Chief Executive
Officer other than in connection with a permitted change-of-control transaction, (c) materially reduce his compensation, or (d)
assign or transfer our rights under the License Agreement or the esmethadone intellectual property without Dr. Traversa’s
consent, in each case (termination or the events in (a) through (d)) during the period commencing on the effective date and ending
on the later of five years from the original effective date of the License Agreement or December 31, 2022 (the “Key Man Term”).
The December 2019 amendment to the License Agreement made certain clarifications to the nature of a termination for Cause, including
to clarify that termination due to Dr. Traversa’s death or disability does not give Licensor the right to terminate the License
Agreement.
Wonpung License Agreement
In 2007, the Company entered into a License Development and
Commercialization Agreement with Wonpung Mulsan Co, a shareholder of the Company. Wonpung has exclusive territorial rights in countries
it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (“ROFR”)
for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement.
If the parties cannot agree to terms of a license agreement then the Company shall be able to engage in discussions with other
potential licensors. As of March 2021, no discussions are active between the Company and Wonpung.
The Company received an upfront license
fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing.
The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing
agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability
of a generic product to such licensed product in the licensed territory.
Key
Strengths
We
believe that the key elements for our market success include:
●
Compelling lead product opportunity, esmethadone currently in Phase 3 trial for the adjunctive treatment of MDD.
●
Successful Phase 1 safety studies of esmethadone and strong clinical activity signal in depression established in three independent animal models.
●
Potential in additional multiple indications in underserved markets with large patient population, such as MDD, other affective disorders, and cognitive disorders.
●
Scientific support of leading experts: Our scientific advisors include clinicians and scientists who are affiliated with a number of highly regarded medical institutions such as Harvard, Cornell, Yale, and University of Pennsylvania.
●
Substantial IP portfolio and market protection: approved and filed patent applications provide coverage beyond 2030. In addition, some of our drugs, including esmethadone have also been designated as Orphan Drugs by the FDA, thereby providing seven years of market exclusivity at launch.
Competition
The
pharmaceutical and biotechnology industry is characterized by intense competition, rapid product development and technological
change. Competition is intense among manufacturers of prescription pharmaceuticals and other product areas where we may develop
and market products in the future. Most of our competitors are large, well-established pharmaceutical or healthcare companies
with considerable financial, marketing, sales and technical resources than are available to us. Additionally, many of our competitors
have research and development capabilities that may allow such competitors to develop new or improved products that may compete
with our products. Our products could be rendered obsolete or made uneconomical by the development of new products.
Regarding our competitive position in
the industry, we currently have no product approved for sale.
5
Government
Regulation
Government
authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage,
recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and
export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries
and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities,
require the expenditure of substantial time and financial resources.
FDA Approval Process
In the United States, pharmaceutical products
are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (FD&C Act) and other federal and state
statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval,
labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical
products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial
sanctions, such as FDA refusal to approve pending new drug applications (NDAs), warning or untitled letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.
Pharmaceutical product development for
a new product or certain changes to an approved product in the U.S. typically involves preclinical laboratory and animal tests,
the submission to FDA of an investigational new drug application (IND) which must become effective before clinical testing may
commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication
for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual
time required may vary substantially based upon the type, complexity and novelty of the product or disease.
Preclinical tests include laboratory evaluation
of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and
efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including
good laboratory practices. The results of preclinical testing are submitted to FDA as part of an IND along with other information,
including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical
tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting
period after the submission of each IND is required prior to the commencement of clinical testing in humans. If FDA has neither
commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials
involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified
investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with good clinical
practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical
trial sponsors, administrators and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters
to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients
and subsequent protocol amendments must be submitted to FDA as part of the IND.
6
Clinical trials to support NDAs for marketing
approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of
the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions,
side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials
in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum
dosage, and to identify common adverse effects and safety risks. If a drug demonstrates evidence of effectiveness and an acceptable
safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy
and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit FDA to evaluate
the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases,
FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3
trial with other confirmatory evidence may be sufficient in rare instances, such as where the study is a large multicenter trial
demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality,
irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second
trial would be practically or ethically impossible.
After completion of the required clinical
testing, an NDA is prepared and submitted to FDA. FDA approval of the NDA is required before marketing of the product may begin
in the U.S. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating
to the product’s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting an NDA is substantial.
The submission of most NDAs is additionally subject to a substantial application user fee, and the applicant under an approved
NDA is also subject to an annual program fee for each prescription product. These fees are typically increased annually. Sponsors
of applications for drugs granted Orphan Drug Designation are exempt from these user fees.
FDA may also refer applications for novel
drug products, or drug products that present difficult questions of safety or efficacy, to an outside advisory committee –
typically a panel that includes clinicians and other experts – for review, evaluation and a recommendation as to whether
the application should be approved. FDA is not bound by the recommendation of an advisory committee, but it generally follows such
recommendations.
Before approving an NDA, FDA will typically
inspect one or more clinical sites to assure compliance with GCP. Additionally, FDA will inspect the facility or the facilities
at which the drug is manufactured. FDA will not approve the product unless compliance with current good manufacturing practices
(cGMPs) is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the
indication studied.
Fast Track Designation
FDA is required to facilitate the development,
and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for
which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under
the Fast Track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication
as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA must determine if the drug candidate
qualifies for Fast Track Designation within 60 days of receipt of the sponsor’s request.
If a submission is granted Fast Track Designation,
the sponsor may engage in more frequent interactions with FDA, and FDA may review sections of the NDA before the application is
complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining
information and the applicant pays applicable user fees. However, FDA’s time period goal for reviewing an application does
not begin until the last section of the NDA is submitted. Additionally, Fast Track Designation may be withdrawn by FDA if FDA believes
that the designation is no longer supported by data emerging in the clinical trial process.
Post-Approval Requirements
Once an NDA is approved, a product will
be subject to certain post-approval requirements. For instance, FDA closely regulates the post-approval marketing and promotion
of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific
and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications
and in accordance with the provisions of the approved labeling.
7
Adverse event reporting and submission
of periodic reports are required following FDA approval of an NDA. FDA also may require post-marketing testing, known as Phase
4 testing, REMS and surveillance to monitor the effects of an approved product, or FDA may place conditions on an approval that
could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures
must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register
their establishments with FDA and certain state agencies. Registration with FDA subjects entities to periodic unannounced inspections
by FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must
continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory
authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if
it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.
Generic Competition
In seeking approval for a drug through
an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant’s product. Upon approval
of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Approved Drug Products
with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited
by potential generic competitors in support of approval of an abbreviated new drug application (ANDA). An ANDA provides for marketing
of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown
through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence
testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or
effectiveness of their drug product. Drugs approved in this way are commonly referred to as “generic equivalents” to
the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.
The ANDA applicant is required to certify
to the FDA concerning any patents listed for the approved product in the FDA’s Orange Book. Specifically, the applicant must
certify that (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the
listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the
listed patent is invalid or will not be infringed by the new product (a Paragraph IV certification). The ANDA applicant may also
elect to submit a section viii statement certifying that its proposed ANDA label doe s not contain (or carve out) any language
regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge
the listed patents or certifies that the listed patents will not be infringed by the new product, the ANDA application will not
be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph
IV certification, the NDA and patent holders may then initiate a patent infringement lawsuit in response. The filing of a patent
infringement lawsuit within 45 days of the receipt of a such certification automatically prevents the FDA from approving the ANDA
until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that
is favorable to the ANDA applicant. Exclusivity
Upon NDA approval of a new chemical entity
(NCE) such as esmethadone, which is a drug that contains no active moiety that has been approved by FDA in any other NDA, that
drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version
of that drug. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there
is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the
expiration of the exclusivity period. Certain changes to a drug, such as the addition of a new indication to the package insert,
can be the subject of a three-year period of exclusivity if the application contains reports of new clinical investigations (other
than bioavailability studies) conducted or sponsored by the sponsor that were essential to approval of the application. FDA cannot
approve an ANDA for a generic drug that includes the change during the period of exclusivity.
8
Patent Term Extension
After NDA approval, owners of relevant
drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the
drug’s testing phase (the time between IND application and NDA submission) and all of the review phase (the time between
NDA submission and approval up to a maximum of five years). The time can be shortened if FDA determines that the applicant did
not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years, and only one patent
can be extended. For patents that might expire during the application phase, the patent owner may request an interim patent extension.
An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent
extension granted, the post-approval patent extension is reduced by one year. The director of the United States Patent and Trademark
Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim
patent extensions are not available for a drug for which an NDA has not been submitted.
Controlled Substances
The active ingredients in esmethadone are
listed by the United States Drug Enforcement Administration, or DEA, as controlled substances under the U.S. Controlled Substances
Act of 1970, or CSA. The Controlled Substances Act and its implementing regulations establish a closed chain of distribution for
entities handling controlled substances. The CSA and regulations enforced by the DEA impose registration, security, recordkeeping
and reporting, storage, manufacturing, distribution, importation, exportation, and other requirements on entities handling controlled
substances. The DEA requires those individuals or entities that handle controlled substances to comply with these requirements
in order to ensure legitimate use and prevent the diversion of controlled substances to illicit channels of commerce.
Facilities that manufacture, distribute,
import or export any controlled substance must register annually with the DEA. The DEA registration is specific to a particular
location, activity, and controlled substance schedule.
The CSA categorizes controlled substances
into one of five schedules – Schedule I, II, III, IV, or V – depending on the potential for abuse and physical or psychological
dependence. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in
treatment in the U.S. and lack accepted safety for use under medical supervision. They may not be marketed or sold for dispensing
to patients in the U.S. Pharmaceutical products having a currently accepted medical use and that are otherwise approved for marketing
may be listed as Schedule II, III, IV, or V substances, with Schedule II substances presenting the highest potential
for abuse and physical or psychological dependence, and Schedule V substances presenting the lowest relative potential for
abuse and dependence. Schedule II substances (as well as substances defined as narcotics in any Schedule) are subject to most regulatory
requirements and restrictions, such as recordkeeping, reporting and security. For example, all Schedule II drug prescriptions
must be signed by a physician, physically presented to a pharmacist in most situations unless they are electronically prescribed
pursuant to DEA regulations, and cannot be refilled. Schedules III, IV and V controlled substances are subject to fewer restrictions.
The
DEA inspects manufacturers, distributors, importers, and exporters to review compliance with the CSA and DEA regulations including
security, record keeping and reporting prior to issuing a controlled substance registration. The specific security requirements
vary by the type of business activity and the schedule and quantity of controlled substances handled by the registrant. The most
stringent requirements apply to manufacturers of Schedule I and Schedule II substances. Manufacturers and distributors
must also submit regular reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III
narcotic substances, and other designated substances. All DEA registrants must report any controlled substance thefts or significant
losses and must obtain authorization to destroy or dispose of controlled substances. In addition to maintaining an importer and/or
exporter registration, importers and exporters of controlled substances must obtain a permit for every import or export of a Schedule
I or II substance and a narcotic substance in Schedule III, IV and V. For all other drugs in Schedule III, IV and V, importers
and exporters must submit an import or export declaration.
The
DEA establishes annually an aggregate production quota for the amount of substances within Schedules I and II and certain Schedule
III substances, that may be produced in the U.S. based on the DEA’s estimate of the quantity needed to meet legitimate medical,
scientific, research and industrial needs. The aggregate quota for each controlled substance is allocated among the various individual
manufacturers through an application process. Manufacturers may not exceed the manufacturing or procurement quota granted in a
given year. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms.
The DEA may adjust aggregate production quotas and individual manufacturing or procurement quotas from time to time during the
year, although the DEA has substantial discretion concerning whether or not to make such adjustments.
9
Failure to maintain compliance with applicable
DEA requirements, particularly as manifested in the loss or diversion of controlled substances, can result in an enforcement action.
The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those
registrations. In certain circumstances, violations could lead to criminal prosecution.
The various states, commonwealths, and
the District of Columbia, also regulate controlled substances and impose similar licensing, recordkeeping, and reporting requirements
on entities that handle controlled substances. Entities must independently comply with the various state requirements in addition
to the federal controlled substance requirements.
Other Healthcare Laws
In the United States, biotechnology company
activities are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not
limited to, the Centers for Medicare & Medicaid Services (CMS), other divisions of the U.S. Department of Health and Human
Services (e.g., the Office of Inspector General and the Office for Civil Rights), the U.S. Department of Justice (DOJ) and individual
U.S. Attorney offices within the DOJ, and state and local governments. For example, research, sales, marketing and scientific/educational
grant programs have to comply with the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws,
the privacy and security provisions of the Health Insurance Portability and Accountability Act (HIPAA) and similar state laws,
each as amended, as applicable.
Also, many states have similar fraud and
abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several
states, apply regardless of the payor.
Data privacy and security regulations by
both the federal government and the states in which business is conducted may also be applicable. HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements
relating to the privacy, security and transmission of individually identifiable health information. HIPAA requires covered entities
to limit the use and disclosure of protected health information to specifically authorized situations and requires covered entities
to implement security measures to protect health information that they maintain in electronic form. Among other things, HITECH
made HIPAA’s security standards directly applicable to business associates, independent contractors or agents of covered
entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity.
HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable
to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal
courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions.
In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ
from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Insurance Coverage and Reimbursement
Significant uncertainty exists as to the
insurance coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States,
sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability
of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs
in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These
third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether
a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor
will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary,
which might not include all of FDA-approved drugs for a particular indication. A payor’s decision to provide coverage for
a drug product does not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for drug
products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming
and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
10
Corporate
Information
Our
principal executive offices are located at 880 Third Avenue, 12th Floor, New York, New York 10022 and our telephone number is
(646) 876-3459. Our website address is www.relmada.com. The information contained in, or that can be accessed
through, our website is not part of, and is not incorporated in, this Report.
A vailable
Information
Reports
we file with the Securities and Exchange Commission (SEC) pursuant to the Exchange Act of 1934, as amended (the Exchange Act),
including annual and quarterly reports, and other reports we file, can be inspected and copied at the public reference facilities
maintained by the SEC at 100 F Street NE, Washington, D.C. 20549.
Human Capital
As of December 31, 2020, we had a total
of 14 employees. We understand people are our greatest asset and that our innovation and operational excellence are ultimately
noted in our human capital. Our success depends in large part on our ability to recruit, develop and retain a qualified, productive,
and engaged workforce.
Inclusion & Diversity
Inclusion and
diversity is a focus of our corporate human capital strategy. By embracing inclusion and diversity, we enhance our work environment
and drive business success. We endeavor to create a culture of inclusion in which our employees feel empowered to bring their full,
authentic selves to work and pursue their professional goals in a setting of equality. Fostering such a culture welcomes different
perspectives and generates innovation and growth. We honor the diversity of our employees—in gender, race/ethnicity, age,
gender identity, sexual orientation, socio-economic status, language, nationality, abilities and life experiences. As of December
31, 2020, our employee population was approximately 64% female.
Total Rewards
and Employee Engagement
We maintain a
competitive compensation and benefits package including incentive compensation tied to both company and individual performance,
and retirement benefits. Our performance-based compensation strategy is designed to recognize and reward employees for their contribution
to our success, and we strive to provide strong, equitable incentives for performance. Compensation is comprised of two elements:
base compensation, which is determined based upon a number of factors, including size, scope and impact of the employee’s
role, the market value associated with the employee’s role, leadership skills, length of service and individual performance;
and an annual bonus, which is a cash award determined based on a combination of individual and company performance during the period
to which the bonus relates. We seek to determine compensation on the basis of merit and without regard to demographic characteristics.
During 2020, we employed a third-party consultant to assist us in evaluating our pay practices. In conducting this exercise, we
found no meaningful difference in compensation based upon gender, race or any other defining characteristic examined.
COVID-19 Response
We moved swiftly
in our response to the COVID-19 pandemic to promote the safety of our associates and best serve our members and communities. In
March of 2020, we transitioned the out workforce to remote work environments, while maintaining service operations. We continued
to pay employees who missed work for COVID-19 related reasons and avoided role reductions as a direct result of COVID-19.
11
ITEM 1A.
RISK FACTORS
Our
business faces significant risks. You should carefully consider the risks described below, together with all of the other information
included in our filings with the United States Securities and Exchange Commission (SEC) when evaluating our business. If any of
the following risks actually occurs, our business, financial condition or results of operations could be materially adversely
affected and the trading price of shares of our common stock could decline. The occurrence of any of the following risks could
cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and
those we may make from time to time.
Summary of Risks
This section provides a summary of the
risks that may impact our performance in the future. For details of our various risk factors and their impacts, see “Risk
Factors Discussion.”
Our risk factors are organized into the
following categories: 1) Risks related to our business, 2) Risks related to clinical and regulatory matters, 3) Risks related
to our intellectual property, 4) Risks related to government regulations, 5) Risks related to our reliance on third parties, and
6) Risks related to our common stock,
Risks related
to our business
Business risks include risks associated
with our products and regulatory approval, licensing agreements, historical losses, managing growth, acquisitions and the COVID-19
pandemic. In general, the risks related to our business can cause variability in the future profits of the Company.
Risks related
to Clinical and Regulatory Matters
Clinical and regulatory
matters include risks associated with clinical trials and the future ability to commercially market the product. In order for any
of our products to be commercialized and produce future profits, successful trials need to be completed with supporting data to
receive regulatory approval. Failing to complete the trial will significantly increase our cost of doing business. In addition,
the active ingredient in our products is a controlled substance which can affect the supply available for clinical trials, as well
as commercial sales. A limited supply could increase the time needed to complete clinical trials and overall costs including product
liability claims. We could also face potential fines or reputational risk if we do not comply. Developments from competitors and
the ability to obtain market exclusivity could also negatively impact future profits.
Risks related
to our intellectual property
Our products depend
upon securing and protecting critical intellectual property. Patent positions are highly uncertain and involve complex legal and
factual questions. Infringing upon a patents or trade secrets could force us to cease or alter our product development efforts
or obtain a license to continue to develop or sale our products. These risks could not only impact the future profits of the company
but also create adverse publicity for us.
Risks related
to government regulations
We are required
to comply with various federal and state pharmaceutical and healthcare laws and regulations, and to maintain secure systems to
protect sensitive confidential information. Complying with the various regulations can increase our cost of doing business. We
could also face potential fines or reputational risk if we do not comply. Litigation or investigations can increase costs, negatively
affect our operating results and create adverse publicity for us.
Risks related
to our reliance on third parties
The Company relies on third parties to
conduct preclinical and clinical studies, as well as to manufacture our product candidates. Third parties’ failure to perform
the trials as contractually require could impact our ability to obtain regulatory approval. If manufacturers fail to meet our requirements
and strict regulatory requirements, our product development and commercialization efforts may be materially harmed.
Risks related
to our common stock
Common stocks
risks includes risks associated with the limited market for our common stock, a potential issuance of a substantial number of additional
shares, stock price volatility, and reporting requirements of federal securities laws. The net effect of these risks can include
reductions in future profits, additional operating expenses, inability to meet liquidity needs, inability to access capital and
increased cost of capital.
12
Risk Factors Discussion
Risk
Related to Our Business
Our business depends on the success
of esmethadone (d-methadone, dextromethadone, REL-1017), our only product candidate currently under clinical development, which
has recently entered into a pivotal clinical trial for the adjunctive treatment of MDD. If we are unable to obtain regulatory approval
for and successfully commercialize REL-1017 or other future product candidates, or we experience significant delays in doing so,
our business will be materially harmed.
To date, the primary focus of our product
development has been esmethadone (d-methadone, dextromethadone, REL-1017) for the adjunctive treatment of patients with MDD. Currently,
esmethadone is our only product candidate under clinical development. This may make an investment in our company riskier than similar
companies that have multiple product candidates in active development and that therefore may be able to better sustain a setback
of a lead candidate. Successful continued development and ultimate regulatory approval of esmethadone for the adjunctive treatment
of MDD, and potentially as a monotherapy for MDD, or other indications is critical to the future success of our business. We have
invested, and will continue to invest, a significant portion of our time and financial resources in the clinical development of
esmethadone. If we cannot successfully develop, obtain regulatory approval for and commercialize esmethadone, we may not be able
to continue our operations. The future regulatory and commercial success of esmethadone is subject to a number of risks, including
the following:
●
we
may not be able to obtain adequate evidence from clinical trials of efficacy and safety for esmethadone for the adjunctive
treatment of MDD, monotherapy for MDD or other indications;
●
we may not be able
to demonstrate that the benefits of esmethadone for the adjunctive treatment of MDD, monotherapy for MDD or other indications
outweigh the risks;
●
in our clinical
trials for esmethadone, enrollment may be slower than anticipated and we may need additional clinical trial sites than originally
planned, which could delay our clinical trial progress;
●
the results of our
clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign regulatory
authorities for marketing approval;
●
patients in our
clinical trials may suffer serious adverse effects for reasons that may or may not be related to esmethadone, which could
delay or prevent further clinical development;
●
the standards implemented
by clinical or regulatory agencies may change at any time and we cannot be certain what efficacy endpoints the FDA or foreign
clinical or regulatory agencies may require in pivotal clinical trials with respect to the adjunctive treatment of MDD, monotherapy
for MDD or any other indication for the approval of esmethadone;
●
the results of later
stage clinical trials may not be as favorable as the results we have observed to date in our preclinical studies and Phase
1 and 2 clinical trials;
●
we cannot be certain
of the number and type of clinical trials and preclinical or toxicology studies that the FDA or other regulatory agencies
will require in order to approve esmethadone for the adjunctive treatment of MDD, monotherapy for MDD or any other indication;
●
we may not have
sufficient financial and other resources to complete the necessary clinical trials for esmethadone, including, but not limited
to, the clinical trials needed to obtain drug approval;
●
if approved for
the adjunctive treatment of MDD or as a monotherapy for MDD, esmethadone will likely compete with products that may reach
approval prior to esmethadone, products that are currently approved for the adjunctive treatment of MDD or as a monotherapy
for MDD and the off-label use of currently marketed products for MDD; and
●
we may not be able
to obtain, maintain or enforce our patents and other intellectual property rights.
Esmethadone and any future product candidates will be subject to rigorous and extensive clinical
trials and extensive regulatory approval processes implemented by the FDA and comparable foreign regulatory authorities before
obtaining marketing approval from these regulatory authorities, if at all. The drug development and approval process is lengthy
and expensive, and approval is never certain. Investigational new drugs, such as esmethadone, may not prove to be safe and effective
in clinical trials. We have no direct experience as a company in conducting later stage clinical trials required to obtain regulatory
approval. We may be unable to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers
of participants or begin or successfully complete clinical trials in a timely fashion, if at all. In addition, the design of a
clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial
may not become apparent until the clinical trial is well advanced. Because we have limited experience as a company designing clinical
trials, we may be unable to design and execute a clinical trial to support regulatory approval.
13
There
is a high failure rate for drugs and biological products proceeding through clinical trials. Failure can occur at any time during
the clinical trial process. The results of preclinical studies and early clinical trials of esmethadone or any future product
candidate may not be predictive of the results of later-stage clinical studies or trials and the results of studies or trials
in one set of patients or line of treatment may not be predictive of those obtained in another. In fact, many companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials even after achieving
promising results in preclinical studies and earlier stage clinical trials. In addition, data obtained from preclinical and clinical
activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Owing in part to the
complexity of biological pathways, esmethadone or any future product candidate may not demonstrate in patients the biochemical
and pharmacological properties we anticipate based on laboratory studies or earlier stage clinical trials, and they may interact
with human biological systems or other drugs in unforeseen, ineffective or harmful ways. The number of patients exposed to product
candidates and the average exposure time in the clinical development programs may be inadequate to detect rare adverse events
or findings that may only be detected once a product candidate is administered to more patients and for greater periods of time.
To date, our Phase 2 clinical study has involved a small population of subjects with MDD, and, because of the small sample size
in such trial, the results of this clinical trial may be subject to substantial variability and may not be indicative of either
future top-line results or final results. If we are unable to successfully demonstrate the safety and efficacy of esmethadone
or other future product candidates and receive the necessary regulatory approvals, our business will be materially harmed.
Even if we do receive regulatory approval
to market esmethadone, any such approval may be subject to limitations on the indicated uses or patient populations for which
we may market the products. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development
programs, we may be unable to successfully develop or commercialize esmethadone. If we or any of our future development collaborators
are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize esmethadone, we may not
be able to generate sufficient revenue to continue our business.
Top-line results may not accurately
reflect the complete results of the clinical study.
In October 2019, we reported top-line data
from our Phase 2a study of esmethadone in adults with MDD who did not respond to one to three courses of antidepressant treatment
in their current episode. Although the top-line data indicated that subjects experienced statistically significant improvement
of their depression compared to subjects in the placebo group, as well as a favorable safety and tolerability profile, the top-line
data are based on preliminary analysis of key pharmacokinetic, safety and efficacy data, and such data may change following a more
comprehensive review of the data and may not accurately reflect the complete results of the study. Preliminary data also remain
subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data. As a result, preliminary data should be viewed with caution until the final data are available.
Our license
agreement for esmethadone, our only product candidate currently under clinical development, could terminate under certain circumstances,
including if we terminate our chief executive officer except for cause, and we would be unable to conduct our business as planned.
In January 2018,
we entered into an Intellectual Property Assignment Agreement (the “Assignment Agreement”) and License Agreement
(the License Agreement and together with the Assignment Agreement, the Agreements), with Dr. Charles E. Inturrisi and Dr. Paolo
Manfredi (collectively, the “Licensor”). Pursuant to the Assignment Agreement, we assigned our existing rights, including
patents and patent applications, to esmethadone in the context of psychiatric use to Licensor, and pursuant to the License Agreement,
Licensor then granted us an exclusive perpetual, worldwide license under the assigned intellectual property rights as well as patents
and know-how covering certain new inventions developed by Licensor and relating to esmethadone in neurological and other uses,
to develop and commercialize esmethadone in all fields of use. The License Agreement also grants to us rights in all future inventions
developed by Licensor, whether or not in collaboration with us that relate in any way to esmethadone or the use thereof. The License
Agreement was amended in December 2019 to modify certain termination rights relating to the Chief Executive Officer, which are
described further below.
If we develop
any new inventions relating to esmethadone, we are required to do so in collaboration with Licensor, and to file patents covering
such inventions jointly in the name of the Company and Licensor. All such future inventions or patents shall be jointly owned by
us and Licensor and, will be included in and subject to the financial and other terms of the License Agreement.
The License Agreement
includes standard termination rights for Licensor in the event of our insolvency, challenge of the licensed patents and uncured
material breach of our obligations under the License Agreement. In addition, the License Agreement contains certain “Key
Man” provisions such that the Licensor may terminate the License Agreement if we terminate the employment of our Chief Executive
Officer Mr. Sergio Traversa for any reason other than for specified causes determined by a majority of our Board of Directors (including
fraud, gross negligence, unauthorized use of our confidential information, conduct including harassment or discrimination, breach
of fiduciary duty or uncured material breach), or if we (a) substantially modify Mr. Traversa’s job responsibilities or decision-making
rights in connection with the development and commercialization of esmethadone, (b) remove him from the role of Chief Executive
Officer other than in connection with a permitted change-of-control transaction, (c) materially reduce his compensation, or (d)
assign or transfer our rights under the License Agreement or the esmethadone intellectual property without Mr. Traversa’s
consent, in each case (termination or the events in (a) through (d) during the period commencing on the effective date and ending
on the later of five years from the original effective date of the License Agreement on December 31, 2022 (the “Key Man Term”).
The December 2019 amendment to the License Agreement made certain clarifications to the nature of a termination for Cause, including
to clarify that termination due to Mr. Traversa’s death or disability does not give Licensor the right to terminate the License
Agreement.
14
As
a result of the provisions described above, we are limited in our ability to terminate, as well as to decrease the salary or authority
of, our Chief Executive Officer until December 31, 2022. In addition, the agreement provides that any assignor that we assign
the agreement to must agree in writing to all terms of the license, including the key man provisions, and as noted above, our
Chief Executive Officer has the right to consent to any such assignment of the agreement unless previously terminated for cause
or due to death. As the license agreement relates to our only product candidate currently under clinical development, these provisions may
be deemed to have an anti-takeover effect and may delay, deter or prevent a tender offer or takeover attempt that a stockholder
might consider to be in its best interests, including attempts that might result in a premium being paid over the market price
for the shares held by stockholders. If we fail to comply with the terms of the License Agreement, our rights to those patents
may be terminated, and we will be unable to conduct our business.
We
have generated no revenue from commercial sales to date and our future profitability is uncertain.
We
have a limited operating history and our business is subject to all of the risks inherent in the establishment of a new business
enterprise. Our likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays
frequently encountered in connection with this. Since we began our business, we have focused on research, development and clinical
trials of product candidates, and have incurred significant losses since inception and generated no product revenues. If we continue
to incur operating losses and fail to become a profitable company, we may be unable to continue our operations. We expect to continue
to operate at a net loss for at least the next several years as we continue our research and development efforts, continue to
conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that
the products under development by us will be approved for sales in the US or elsewhere. Furthermore, there can be no assurance
that if such products are approved they will be successfully commercialized, and the extent of our future losses and the timing
of our profitability are highly uncertain.
International
commercialization of our product candidates faces significant obstacles.
We
may plan to commercialize some of our products internationally through collaborative relationships with foreign partners. We have
limited foreign regulatory, clinical and commercial resources. Future partners are critical to our international success. We may
not be able to enter into collaboration agreements with appropriate partners for important foreign markets on acceptable terms,
or at all. Future collaborations with foreign partners may not be effective or profitable for us. We will need to obtain approvals
from the appropriate regulatory, pricing and reimbursement authorities to market any of our proposed products internationally,
and we may be unable to obtain foreign regulatory approvals. Pursuing foreign regulatory approvals will be time-consuming and
expensive. The regulations can vary among countries and foreign regulatory authorities may require different or additional clinical
trials than we conducted to obtain FDA approval for our product candidates. In addition, adverse clinical trial results, such
as death or injury due to side effects, could jeopardize not only regulatory approval, but if approval is granted, may also lead
to marketing restrictions. Our product candidates may also face foreign regulatory requirements applicable to controlled substances.
We
have a history of losses and we may never achieve or sustain profitability.
We have incurred substantial losses since
our inception, and we may not achieve profitability for the foreseeable future, if at all. Since inception, we have an accumulated
deficit of approximately $179.3 million at December 31, 2020. The Company had cash, cash equivalents and short term investments
of approximately $117.1 million at December 31, 2020. Even if we succeed in developing and commercializing one or more of our product
candidates, we expect to incur substantial net losses and negative cash flows for the foreseeable future due in part to increasing
research and development expenses, including clinical trials, and increasing expenses from leasing additional facilities and hiring
additional personnel. As a result, we will need to generate significant revenues in order to achieve and maintain profitability.
We may not be able to generate these revenues or achieve profitability in the future. Even if we do achieve profitability, we may
not be able to sustain or increase profitability.
We
have a limited operating history upon which to base an investment decision.
Our
limited operating history may limit your ability to evaluate our prospects due to our limited historical financial data and our
unproven potential to generate profits. You should evaluate the likelihood of financial and operational success in light of the
risks, uncertainties, expenses and difficulties associated with an early-stage business, many of which may be beyond our control,
including:
●
our potential inability
to continue to undertake preclinical studies, pharmaceutical development and clinical trials,
●
our potential inability
to obtain regulatory approvals, and
●
our potential inability
to manufacture, sell and market our products.
Our
operations have been limited to organizing and staffing, on a limited basis, our company, acquiring, developing and securing our
proprietary technology and undertaking preclinical studies and early stage clinical trials of our principal product candidates.
These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability
of investing in our common stock.
15
Our
ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
As of December 31, 2020, we had Federal, New York State and
New York City net operating loss (NOL) carryforwards of approximately $72,507,000, $68,854,000 and $68,470,000, respectively, which
begin expiring in 2027, 2032 and 2032, respectively. Under U.S. federal tax legislation enacted in 2017, informally titled the
Tax Cuts and Jobs Act, or Tax Act, federal NOLs incurred in 2018 and in future years may be carried forward indefinitely, but the
deductibility of such federal NOLs is limited to 80% of taxable income in the year. It is uncertain if and to what extent various
states will conform to the Tax Act. Under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, if a corporation
undergoes an “ownership change” (generally defined as a greater than 50 percentage-point cumulative change (by value)
in the equity ownership of certain stockholders over a rolling three-year period), the corporation’s ability to use its pre-change
NOLs and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may also experience
ownership changes as a result of stock offerings or as a result of subsequent shifts in our stock ownership, some of which are
outside our control. We have not completed an analysis to determine whether any such limitations have been triggered. If any were
determined to be triggered, our ability to use our current NOLs and other pre-change tax attributes to offset post-change taxable
income or taxes would be subject to limitation. We will be unable to use our NOLs if we do not attain profitability sufficient
to offset our available NOLs prior to their expiration.
We
may not be successful in hiring and retaining key employees.
Our
future operations and successes depend in large part upon the continued service of key members of our senior management team whom
we are highly dependent upon to manage our business, specifically Dr. Sergio Traversa, our Chief Executive Officer. If he terminates
employment with us, such a departure would have a material adverse effect on our business.
Our future success also depends on our
ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. We currently only have 14 full time employees and are likely to hire additional qualified personnel with expertise in
nonclinical pharmacology and toxicology, pharmaceutical development, clinical research, regulatory affairs, manufacturing, sales
and marketing. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research
institutions. Competition for such individuals, particularly in the United States, is intense, and we may not be able to hire sufficient
personnel to support our efforts. There can be no assurance that these professionals will be available in the market, or that we
will be able to retain existing professionals or to meet or to continue to meet their compensation requirements. Furthermore, the
cost base in relation to such compensation, which may include equity compensation, may increase significantly, which could have
a material adverse effect on us. Failure to establish and maintain an effective management team and work force could adversely
affect our ability to operate, grow and manage our business.
Managing
our growth as we expand operations may strain our resources.
We expect to need to grow rapidly in order
to support additional, larger, and potentially international, pivotal clinical trials of our drug candidates, which will place
a significant strain on our financial, managerial and operational resources. In order to achieve and manage growth effectively,
we must continue to improve and expand our operational and financial management capabilities. Moreover, we will need to increase
staffing and to train, motivate and manage our employees.
We
may expand our business through the acquisition of rights to new drug candidates that could disrupt our business, harm our financial
condition and may also dilute current stockholders’ ownership interests in our company.
Our
business strategy includes expanding our products and capabilities, and we may seek acquisitions of drug candidates or technologies
to do so. Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity
securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time
of acquisition; difficulties in assimilating the acquired technologies or the operations of the acquired companies; diverting
our management’s attention away from other business concerns; risks of entering markets in which we have limited or no direct
experience; and the potential loss of our key employees or key employees of the acquired companies.
We
cannot assure you that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value
or worth of an acquired product, company or business. In addition, our future success would depend in part on our ability to manage
the rapid growth associated with some of these acquisitions. We cannot assure you that we will be able to make the combination
of our business with that of acquired products, businesses or companies work or be successful. Furthermore, the development or
expansion of our business or any acquired products, business or companies may require a substantial capital investment by us.
We may not have these necessary funds or they might not be available to us on acceptable terms or at all. We may also seek to
raise funds by selling shares of our preferred or common stock, which could dilute each current stockholder’s ownership
interest in us.
Business
interruptions could limit our ability to operate our business.
Our
operations as well as those of our collaborators on which we depend are vulnerable to damage or interruption from computer viruses,
human error, natural disasters, electrical and telecommunication failures, international acts of terror and similar events. We
have not established a formal disaster recovery plan and our back-up operations and our business interruption insurance may not
be adequate to compensate us for losses we may suffer. A significant business interruption could result in losses or damages incurred
by us and require us to cease or curtail our operations.
16
Our
business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.
In December 2019, a novel strain of COVID-19
was reported in China. Since then, COVID-19 has spread globally, to include the United States. The spread of COVID-19 has resulted
in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of
a new disease, on March 11, 2020. Many countries around the world have imposed quarantines, travel restrictions, limitations on
gatherings, closures of businesses and other social distancing measures.
As
local jurisdictions continue to put restrictions in place, our ability to continue to operate our business may also be limited.
Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially
affect our business, financial condition and results of operations.
The COVID-19 pandemic and efforts to contain
the outbreak have led to economic disruption, including declines in interest rates, extreme volatility in financial markets, fluctuations
in foreign currency exchange rates, reduced economic activity and a sharp increase in unemployment claims. While the potential
economic impact brought by COVID-19 may be difficult to assess or predict, a more protracted pandemic could result in significant
disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our
liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business
and the value of our common shares.
The
continued spread of COVID-19 globally could also adversely affect our planned clinical trial operations, including our ability
to initiate the trials on the expected timelines and recruit and retain patients and principal investigators and site staff who,
as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, the COVID-19
outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions
in travel, potential unwillingness of patients to enroll in trials at this time, or the inability of patients to comply with clinical
trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. In addition, we
rely on independent clinical investigators, contract research organizations and other third-party service providers to assist
us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect
their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us.
Additionally,
COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee
resources or forced furlough of government employees.
The global outbreak of COVID-19 continues
to rapidly evolve. The ultimate long-term impact of COVID-19 is highly uncertain and cannot be predicted with confidence. In addition,
since COVID-19 is a pandemic, it could materially affect our operations globally, including at our headquarters in the New York
City area and at our future clinical trial sites throughout the globe.
Our
business could be adversely affected by health epidemics in regions where we have significant manufacturing and distribution facilities,
concentrations of clinical trial sites or other business operations.
The
ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet
know the full extent of potential delays or impacts on our business, our supply chain, clinical trials, healthcare systems or
the global economy as a whole. However, these effects could have a material impact on our operations, and, therefore, we will
continue to monitor the COVID-19 situation closely and implement risk mitigation as needed.
Risks
Related to Clinical and Regulatory Matters
If
we or our potential collaborators fail to obtain the necessary regulatory approvals, or if such approvals are limited, we and
our potential collaborators will not be allowed to commercialize our drug candidates, and we will not generate product revenues.
Satisfaction
of all regulatory requirements for commercialization of a drug candidate typically takes many years, is dependent upon the type,
complexity and novelty of the drug candidate, and requires the expenditure of substantial resources for research and development.
Our research and clinical approaches may not lead to drugs that the FDA considers safe for humans and effective for indicated
uses we are studying. The FDA may require studies in addition to those we plan to conduct, in which case we or our collaborators
would have to expend additional time and resources and would likely delay the date of potentially receiving regulatory approval.
The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes
in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals would:
●
delay commercialization
of, and product revenues from, our drug candidates; and
●
diminish the competitive
advantages that we may have otherwise enjoyed, which would have an adverse effect on our operating results and financial condition.
17
Even
if we or our collaborators comply with all FDA regulatory requirements, our drug candidates may never obtain regulatory approval.
If we or our collaborators fail to obtain regulatory approval for any of our drug candidates we will have fewer commercial products,
if any, and corresponding lower product revenues, if any. Even if our drug candidates receive regulatory approval, such approval
may involve limitations on the indications and conditions of use or marketing claims for our products. Further, later discovery
of previously unknown problems or adverse events could result in additional regulatory restrictions, including withdrawal of products.
The FDA may also require us or our collaborators to commit to perform lengthy Phase 4 post-approval clinical efficacy or safety
studies. Our expending additional resources on such trials would have an adverse effect on our operating results and financial
condition.
In
jurisdictions outside the United States, we or our collaborators must receive marketing authorizations from the appropriate regulatory
authorities before commercializing our drugs. Regulatory approval processes outside the United States generally include all of
the aforementioned requirements and risks associated with FDA approval.
If
we or our collaborators are unable to design, conduct and complete successful clinical trials, our drug candidates will not be
able to receive regulatory approval.
Before
obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy,
complex and expensive nonclinical testing and clinical trials that the product is both safe and effective for use in each target
indication.
Results
from early clinical trials may not support moving a drug candidate to later-stage clinical trials. Phase 3 clinical trials may
not demonstrate the safety or efficacy of our drug candidates. Success in preclinical studies and early clinical trials does not
ensure that later clinical trials will be successful. Results of later clinical trials may not replicate the results of prior
clinical trials and preclinical studies. Even if the results of Phase 3 clinical trials are positive, we or our collaborators
may have to commit substantial time and additional resources to conducting further preclinical studies and clinical trials before
obtaining FDA approval for any of our drug candidates.
Clinical trials are very expensive and
difficult to design and implement, in part because they are subject to rigorous requirements. The clinical trial process also consumes
a significant amount of time. Furthermore, if participating patients in clinical trials suffer drug-related adverse reactions during
the course of such clinical trials, or if we, our collaborators or the FDA believe that participating patients are being exposed
to unacceptable health risks, such clinical trials will have to be suspended or terminated. Failure can occur at any stage of the
clinical trials, and we or our collaborators could encounter problems that cause abandonment or repetition of clinical trials.
Our clinical trials and our future clinical
trials for esmethadone measure clinical symptoms, such as depression that are not biologically measurable. The primary measure
of depression is subjective and can be influenced by factors outside of our control, and can vary widely from day to day for a
particular patient, and from patient to patient and site to site within a clinical study. The results we have obtained in completed
animal studies or we have observed in our clinical trials conducted to date may not be predictive of results from our future clinical
trials. In addition, clinical trial results from the study of depression are inherently difficult to predict.
We
have no history of developing drug candidates. We do not know whether any of our planned clinical trials will result in marketable
drugs.
In
addition, completion of clinical trials can be delayed by numerous factors, including:
●
delays in identifying
and agreeing on acceptable terms with prospective clinical trial sites;
●
slower than expected
rates of patient recruitment and enrollment;
●
unanticipated patient
dropout rates;
●
increases in time
required to complete monitoring of patients during or after participation in a clinical trial; and
Any
of these delays could significantly impact the timing, approval and commercialization of our drug candidates and could significantly
increase our overall costs of drug development.
We
cannot predict whether regulatory agencies will determine that the data from our clinical trials support marketing approval.
The FDA’s and other regulatory agencies’
decision to approve our depression product candidate will depend on our ability to demonstrate with substantial clinical evidence
through adequate well-controlled clinical trials, that the product candidate is effective, as measured statistically by comparing
the overall improvement in depression in actively-treated patients against improvement in depression in the control group (usually
a placebo control). However, there is a possibility that our data may fail to show a statistically significant difference from
the placebo control or the active control (if applicable). Alternatively, there is a possibility that our data may be statistically
significant, but that the actual clinical benefit of the product candidates may not be considered to be clinically significant,
clinically relevant or clinically meaningful. Even if we believe that the data from our trials will support marketing approval
in the United States or in Europe, we cannot predict whether the agencies will agree with our analysis and approve our applications.
Developments
by competitors may establish standards of care that affect our ability to conduct our clinical trials as planned.
Changes
in standards related to clinical trial design could affect our ability to design and conduct clinical trials as planned. In that
case, both the cost and the amount of time required to conduct a clinical trial could increase.
18
The
DEA through its quota system limits the availability of the active ingredients in certain of our current drug candidates and,
as a result, the Company’s quotas for these ingredients may not be sufficient to complete clinical trials, or to meet commercial
demand or may result in clinical delays.
The U.S. Drug Enforcement Administration,
or DEA, regulates certain controlled substance chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances
considered to present the highest risk of abuse and Schedule V substances the lowest risk. Esmethadone is the single isomer of
methadone, a Schedule II compound, and its handling (including manufacture, research, shipment, storage, sale and use) is subject
to a high degree of federal and state oversight and regulation. Furthermore, the amount of Schedule II substances that can be obtained
for clinical trials and commercial distribution is limited by the DEA through its quota system. Quotas may not be sufficient to
complete clinical trials or meet commercial demand. There is a risk that federal statutes and DEA regulations concerning applicable
quotas may interfere with the supply of the drugs used in clinical trials for our product candidates, and, in the future, the ability
to manufacture and distribute esmethadone in the volume needed to meet commercial demand.
Conducting
clinical trials of our drug candidates or commercial sales of a drug candidate may expose us to expensive product liability claims
and we may not be able to maintain product liability insurance on reasonable terms or at all.
The
risk of product liability is inherent in the testing of pharmaceutical products. If we cannot successfully defend ourselves against
product liability claims, we may incur substantial liabilities or be required to limit or terminate testing of one or more of
our drug candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against product
liability claims could prevent or inhibit the commercialization of our drug candidates. We currently carry clinical trial insurance
but do not carry product liability insurance. If we successfully commercialize our drug candidates, we may face product liability
claims, regardless of FDA approval for commercial manufacturing and sale. We may not be able to obtain such insurance at a reasonable
cost, if at all. Even if our agreements with any current or future corporate collaborators entitle us to indemnification against
product liability losses, such indemnification may not be available or adequate should any claim arise.
If our drug candidates receive regulatory
approval, we and our collaborators will also be subject to ongoing FDA obligations and continued regulatory review, such as continued
safety reporting requirements, and we and our collaborators may also be subject to additional FDA post-marketing obligations or
new regulations, all of which may result in significant expense and limit our and our collaborators’ ability to commercialize
our drugs.
Any regulatory approvals that our drug
candidates receive may also be subject to limitations on the indicated uses for which the drug may be marketed or contain requirements
for costly post-marketing follow-up studies. In addition, if the FDA approves any of our drug candidates, the manufacturing processes,
labeling, packaging, distribution, post-approval monitoring and adverse event reporting, storage, import, export, advertising,
promotion and record keeping for the drug will be subject to extensive and ongoing regulatory requirements. The FDA has significant
post-market authority, including the authority to require labeling changes based on new safety information and to require post-market
studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from
the market. The manufacturing facilities used to manufacture our product candidates will also be subject to periodic review and
inspection by the FDA and other regulatory agencies, including for continued compliance with current good manufacturing practices
(cGMPs) requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing
processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product
from the market. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory
review. The FDA imposes stringent restrictions on manufacturers’ communications regarding use of their products. If we promote
our product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations,
we may be subject to enforcement action. If we or our collaborators, manufacturers or service providers fail to comply with applicable
continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or
they may be subject to, among other things, fines, warning or untitled letters, holds on clinical trials, suspension or withdrawal
of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export
of products, operating restrictions, injunction, civil penalties and criminal prosecution.
The FDA’s policies may change and
additional government regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. For example,
on July 9, 2012, the FDA approved a risk management program, known as a Risk Evaluation and Mitigation Strategy, or REMS,
for extended-release and long-acting opioid analgesics, or ER/LA opioid analgesics. This REMS will require companies affected by
the REMS to make available training for health care professionals who prescribe ER/LA opioid analgesics on proper prescribing practices
and also to distribute educational materials to prescribers and patients on the safe use of ER/LA opioid analgesics. We cannot
predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative
action, either in the United States or abroad.
Fast Track Designation may not lead to a faster development
or regulatory review or approval process.
We have obtained Fast Track Designation for esmethadone for
the adjunctive treatment of MDD. Fast Track Designation is granted if a drug is intended for the treatment of a serious or life-threatening
condition and the drug demonstrates the potential to address unmet medical needs for this condition. Fast Track Designation does
not guarantee a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast
Track Designation if it believes that the designation is no longer supported by data from our clinical development program.
19
We may not be able to obtain marketing
exclusivity under the Hatch-Waxman Amendments or equivalent regulatory data exclusivity protection in other jurisdictions for our
products.
We intend to rely, in part, on Hatch-Waxman
exclusivity for the commercialization of our products in the United States, if approved. The Hatch-Waxman Amendments provide marketing
exclusivity to the first applicant to gain approval of an NDA under specific provisions of the Federal Food, Drug, and Cosmetic
Act. For esmethadone, which we intend to elect to have not be considered the same active ingredient as methadone and therefore
an NCE, we anticipate obtaining 5-year exclusivity. If FDA were to determine that we do not meet the requirements to make the election,
we may not be able to obtain 5-year exclusivity for the product. In addition, under the statute, this election currently may only
be made in an NDA submitted before October 1, 2022. If we do not submit an NDA before that date or if the statute is not amended
to extend the election, we may not obtain 5-year exclusivity for esmethadone, if approved. For esmethadone, which is an NCE, we
anticipate obtaining 5-year exclusivity for a product containing an active moiety that the FDA has not previously approved.
There can be no assurance that European
authorities will grant data exclusivity for our products, because it does not contain a new active molecule. Even if European data
exclusivity is granted for esmethadone, this may not protect us from direct competition. A competitor(s) with a generic version
of our products may be able to obtain approval of its product during our product’s period of data exclusivity, by submitting
a marketing authorization application (MAA) with a less than full package of nonclinical and clinical data.
We may need to focus our future efforts
in new therapeutic areas where we have little or no experience.
Although our primary strategic interest
is in the areas of depression, esmethadone has potential benefits in other therapeutic areas. If our drug development efforts in
depression fail, or if the competitive landscape or investment climate for antidepressant drug development is less attractive,
we may need to change the company’s strategic focus to include development of our product candidates, or of newly acquired
product candidates, for therapeutic areas other than depression. We have very limited drug development experience in other therapeutic
areas and we may be unsuccessful in making this change from a depression company to a company with a focus in areas other than
depression or a company with a focus in multiple therapeutic areas including depression.
Our product candidates contain controlled
substances, the supply of which may be limited by U.S. statutes and regulations, and the use of which may generate public controversy.
The active ingredients in esmethadone are
listed by the DEA as controlled substances under the Controlled Substances Act of 1970. The DEA regulates certain drug substances
in Schedule I, II, III, IV or V, with Schedule I substances considered to present the highest risk of substance abuse and Schedule
V substances the lowest risk. These product candidates are also subject to DEA regulations relating to their handling (i.e., manufacturing,
storage, distribution, prescribing and dispensing procedures).
Products containing controlled substances
may generate public controversy. Opponents of these products may seek restrictions on marketing and withdrawal of any regulatory
approvals. In addition, these opponents may seek to generate negative publicity in an effort to persuade the medical community
to reject these products. Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit
or restrict the introduction and marketing of our product candidates.
Failure to comply with the Controlled
Substances Act or DEA regulations, or the cost of compliance with these regulations, may adversely affect our business.
Esmethadone is subject to extensive regulation
by the DEA. Although esmethadone is substantially devoid of opioid activity, and psychotomimetic effects, the DEA may elect to
designate it as a controlled substance falling under a DEA controlled substance Schedule. Additionally, esmethadone is produced
by separation from racemic methadone, a scheduled drug subject to extensive regulation by the DEA.
The manufacture, shipment, storage, sale
and use of controlled substances are subject to a high degree of regulation, including security, record-keeping and reporting obligations
enforced by the DEA. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to a pharmacist
and may not be refilled. This high degree of regulation can result in significant costs in order to comply with the required regulations,
which may have an adverse effect on the development and commercialization of our product candidates.
The DEA limits the availability and production
of all scheduled substances, including esmethadone, through a quota system. The DEA requires substantial evidence and documentation
of expected legitimate medical and scientific needs before assigning quotas to manufacturers. In future years, we may need greater
amounts of controlled substances to sustain our Phase 3 development program, and we will need significantly greater amounts to
implement our commercialization plans if the FDA approves our proposed formulations. Any delay or refusal by the DEA in establishing
the procurement quota or a reduction in our quota for scheduled controlled substances or a failure to increase it over time as
we anticipate could delay or stop the clinical development or commercial sale of some of our products or product candidates. This
could have a material adverse effect on our business, results of operations, financial condition and prospects.
20
If
a supplier of an active pharmaceutical ingredient (API) or a pharmaceutical excipient fails to provide us sufficient quantities,
we may not be able to obtain an alternative supply on a timely or acceptable basis.
Our
pharmaceutical excipients and other APIs are multisource, although not all sources have an active Drug Master File (DMF) with
the FDA. (A DMF is a submission to the FDA used to provide confidential detailed information about facilities, processes, or articles
used in the manufacturing, processing, packaging, and storing of drugs to support drug development and approval). In addition,
some of the countries for our multisource APIs are not the same as our drug manufacturing locations. Thus, any disruption in supply
from our preferred vendor could result in significant delays with our pharmaceutical development, clinical trials, NDA submission,
NDA approval or commercial sale of the finished product due to contract delays, the need to manufacture a new batch of API, out
of specification API, the need for import and export permits, and the failure of the newly sourced API to perform to the standards
of the previously sourced API.
Modifications to our products may
require new NDA approvals.
After a product candidate receives FDA
approval, expanded uses or uses in new indications of our products may require additional clinical trials and new regulatory approvals,
including additional IND submissions before we can begin clinical development and supplemental NDA approval prior to marketing
and sales. If we are required to conduct additional clinical studies, it would require additional expenditures and harm our operating
results. Delays in obtaining required future approvals could adversely affect our ability to introduce new or enhanced products
in a timely manner, which in turn would harm our future growth.
Delays
in the commencement or completion of pharmaceutical development, manufacturing or clinical testing could result in increased costs
to us and delay our ability to generate revenues.
We
do not know whether our pharmaceutical development, manufacturing or clinical testing will begin on time or be completed on schedule,
if at all. For example, we may encounter delays during the manufacture of pilot scale batches including delays with our contract
development or manufacturing organization, sourcing satisfactory quantities of APIs, narcotic import and export permits, sourcing
of excipients, contract disputes with our third party vendors and manufacturers, or failure of the product to meet specification.
Similar delays may occur a during our cGMP manufacture of the product.
The
commencement and completion of clinical trials can be disrupted for a variety of reasons, including difficulties in:
●
recruiting and enrolling
patients to participate in a clinical trial;
●
obtaining regulatory
approval to commence a clinical trial;
●
reaching agreement
on acceptable terms with prospective clinical research organizations and trial sites;
●
obtaining approval
of the institutional review board (IRB) at each site selected for participation in our clinical trials;
●
manufacturing sufficient
quantities of a product candidate;
●
investigator fraud,
including data fabrication by clinical trial personnel;
●
diversion of controlled
substances by clinical trial personnel; and
A
clinical trial may also be suspended or terminated by us, the FDA or other regulatory authorities due to a number of factors,
including:
●
failure to conduct
the clinical trial in accordance with regulatory requirements or in accordance with our clinical protocols;
●
inspection of the
clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical
hold;
●
unforeseen safety
issues; or
●
inadequate patient
enrollment or lack of adequate funding to continue the clinical trial.
In
addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect
these changes, which could impact the cost, timing or successful completion of a clinical trial. If we experience delays in the
commencement or completion of our clinical trials, the commercial prospects for our product candidates will be harmed, and our
ability to generate product revenues will be delayed. Many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also lead to the denial of regulatory approval of a product candidate.
Conducting successful clinical studies
may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.
Patient
enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size
of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with,
the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators; support staff; the
number of ongoing clinical trials in the same indication that compete for the same patients; and proximity of patients to clinical
sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance.
For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo
extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that
the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may
also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products.
21
Adverse safety outcomes could affect
our ability to conduct our clinical trials or obtain approval of our product candidates.
Serious injury or death resulting from
a failure of one of our drug candidates during current or future clinical trials could result in the FDA delaying our clinical
trials or denying or delaying clearance or approval of a product. Even though an adverse event may not be the result of the failure
of our drug candidate, FDA or an IRB could delay or halt a clinical trial for an indefinite period of time while an adverse event
is reviewed, and likely would do so in the event of multiple such events. Any delay or termination of our current or future clinical
trials as a result of the risks summarized above, including delays in obtaining or maintaining required approvals from IRBs, delays
in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays or termination of clinical
trials as a result of protocol modifications or adverse events during the trials, may cause an increase in costs and delays in
the submission of any NDAs to the FDA, delay the approval and commercialization of our products or result in the failure of the
clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays in the completion of
clinical trials of our products would adversely affect our business and prospects and could cause us to cease operations.
On November 29, 2006, the FDA required
a boxed warning to be added to the Prescribing Information for racemic methadone, a parent compound to our esmethadone related
to cardiac death. Although the decision was based on case reports and not on a controlled clinical trial, as part of the development
of esmethadone we will likely have to conduct a specific study to evaluate the effects of esmethadone on QTc interval prolongation.
QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical
cycle. Drugs that prolong the corrected QT interval (QTc) are associated with an increased risk of serious disturbances in heart
rhythm, potentially leading to sudden death. If we do a QT interval prolongation study in accordance with regulatory guidelines,
there is no assurance that the results of the study will demonstrate an absence of QT interval prolongation with esmethadone. An
adverse safety outcome from such study could result in a similar bolded warning on the label of esmethadone or in a decision not
to approve esmethadone, either one of which could have serious consequences for our continued operation.
Esmethadone may require Risk Evaluation
and Mitigation Strategies (REMS).
Esmethadone, may require REMS. The REMS
may include requirements for special labeling or medication guides for patients, special communication plans to health care professionals
and restrictions on distribution and use. We cannot predict the specific REMS to be required as part of the FDA’s approval
of any of our products. Depending on the extent of the REMS requirements, our costs to commercialize our products may increase
significantly. Furthermore, controlled substances risks that are not adequately addressed through proposed REMS for our product
candidates may also prevent or delay their approval for commercialization.
Our products will face significant
competition in the markets for such products, and if they are unable to compete successfully, our business will suffer.
Our products candidates face, and will
continue to face, intense competition from large pharmaceutical companies, specialty pharmaceutical and biotechnology companies
as well as academic and research institutions. We compete in an industry that is characterized by: (i) rapid technological change,
(ii) evolving industry standards, (iii) emerging competition and (iv) new product introductions. Our competitors have existing
products and technologies that will compete with our products and technologies and may develop and commercialize additional products
and technologies that will compete with our products and technologies. Because several competing companies and institutions have
greater financial resources than us, they may be able to: (i) provide broader services and product lines, (ii) make greater investments
in research and development, (R&D ) , and (iii) carry on larger R&D initiatives. Our competitors also have greater
development capabilities than we do and have substantially greater experience in undertaking nonclinical and clinical testing of
products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. They also have greater name
recognition and better access to customers than us. Our chief competitors include companies such as Johnson and Johnson, Allergan,
Pfizer, Eli Lilly, Sage Therapeutics, and Axsome Therapeutics among others.
We
may be exposed to liability claims associated with the use of hazardous materials and chemicals.
Our
research and development activities involve the controlled use of hazardous materials and chemicals. Although we believe that
our safety procedures for using, storing, handling and disposing of these materials comply with federal, state and local laws
and regulations, we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event
of such an accident, we could be held liable for any resulting damages and any liability could materially adversely affect our
business, financial condition and results of operations. In addition, the federal, state and local laws and regulations governing
the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require us to
incur substantial compliance costs that could materially adversely affect our business and financial condition.
We
may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability
lawsuits.
The
testing and marketing of medical products entail an inherent risk of product liability. We may be held liable if serious adverse
reactions from the use of our product candidates occur. If we cannot successfully defend ourselves against product liability claims,
we may incur substantial liabilities or be required to limit commercialization of our product candidates. Our inability to obtain
sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent
or inhibit the commercialization of pharmaceutical products we develop, alone or with corporate collaborators. We currently do
not carry product liability insurance. We, or any corporate collaborators, may not be able to obtain insurance at a reasonable
cost, if at all. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses,
such indemnification may not be available or adequate if any claim arises.
22
Risks
Related to Our Intellectual Property
Our
business depends upon securing and protecting critical intellectual property.
Our
commercial success will depend in part on our obtaining and maintaining patent, trade secret, copyright and trademark protection
of our technologies in the United States and other jurisdictions as well as successfully enforcing this intellectual property
and defending this intellectual property against third-party challenges. We will only be able to protect our technologies from
unauthorized use by third parties to the extent that valid and enforceable intellectual property protection, such as patents or
trade secrets, cover them. In particular, we place considerable emphasis on obtaining patent and trade secret protection for significant
new technologies, products and processes. Furthermore, the degree of future protection of our proprietary rights is uncertain
because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our
competitive advantage. Moreover, the degree of future protection of our proprietary rights is uncertain for products that are
currently in the early stages of development because we cannot predict which of these products will ultimately reach the commercial
market or whether the commercial versions of these products will incorporate proprietary technologies.
Our
patent position is highly uncertain and involves complex legal and factual questions.
Accordingly,
we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example,
we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and
issued patents; we or our licensors might not have been the first to file patent applications for these inventions; others may
independently develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our
pending patent applications or the pending patent applications of our licensors will result in issued patents; our issued patents
and issued patents of our licensors may not provide a basis for commercially viable technologies, or may not provide us with any
competitive advantages, or may be challenged and invalidated by third parties; and, we may not develop additional proprietary
technologies that are patentable.
As
a result, our owned and licensed patents may not be valid and we may not be able to obtain and enforce patents and to maintain
trade secret protection for the full commercial extent of our technology. The extent to which we are unable to do so could materially
harm our business.
Unpatented
trade secrets, improvements, confidential know-how and continuing technological innovation are important to our scientific and
commercial success. Although we attempt to and will continue to attempt to protect our proprietary information through reliance
on trade secret laws and the use of confidentiality agreements with our corporate partners, collaborators, employees and consultants
and other appropriate means, these measures may not effectively prevent disclosure of our proprietary information, and, in any
event, others may develop independently, or obtain access to, the same or similar information.
Certain
of our patent rights are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our
rights to those patents may be terminated, and we will be unable to conduct our business.
If
we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development
efforts, obtain a license to continue the development or sale of our products, and/or pay damages.
Our
manufacturing processes and potential products may violate proprietary rights of patents that have been or may be granted to competitors,
universities or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents
are issued, the risk increases that our processes and potential products may give rise to claims that they infringe the patents
or trade secrets of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical
testing, manufacturing and marketing of the affected product or process. If any of these actions are successful, in addition to
any potential liability for damages, we could be required to obtain a license in order to continue to conduct clinical tests,
manufacture or market the affected product or use the affected process. Required licenses may not be available on acceptable terms,
if at all, and the results of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume
a substantial portion of our financial resources and the efforts of our personnel.
Our ability to protect and enforce
our patents does not guaranty that we will secure the right to commercialize our patents.
A patent is a limited monopoly right conferred
upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention. This
monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using his invention.
While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention, where other permissions
may be required for permissible commercialization to occur. For example, a drug cannot be marketed without the appropriate authorization
from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented itself, cannot
be commercialized if it infringes the valid patent rights of another party.
23
Intellectual property rights do not
necessarily address all potential threats to our competitive advantage.
The degree of future protection afforded
by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:
●
others may be able to make product that is similar to our current and future product candidates we intend to commercialize that is not covered by the patents that we own or license and have the right to enforce;
●
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
●
it is possible that our future patent applications will not lead to issued patents;
●
issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;
●
our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable.
Risks
Related to Government Regulation
We
may undertake international operations, which will subject us to risks inherent with operations outside of the United States.
Although
we do not have any foreign operations at this time, we intend to seek to obtain market clearances in foreign markets that we deem
to generate significant opportunities. However, even with the cooperating of a commercialization partner, conducting drug development
in foreign countries involves inherent risks, including, but not limited to: difficulties in staffing, funding and managing foreign
operations; unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties
in protecting, acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and
potentially adverse tax consequences.
If
we were to experience any of the difficulties listed above, or any other difficulties, any international development activities
and our overall financial condition may suffer and cause us to reduce or discontinue our international development and registration
efforts.
We
depend on our information technology systems and those of our third-party collaborators, service providers, contractors or consultants.
Our internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail
or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our development programs
or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business
and have a material adverse effect on our reputation, business, financial condition or results of operations.
In
the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual
property, proprietary business information and personal information. Our internal technology systems and infrastructure, and those
of our current or future third-party collaborators, service providers, contractors and consultants are vulnerable to damage from
computer viruses, unauthorized access or use resulting from malware, natural disasters, terrorism, war and telecommunication and
electrical failures, denial-of-service attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other
social engineering attacks, persons inside our organizations (including employees or contractors), loss or theft, or persons with
access to systems inside our organization. Attacks on information technology systems are increasing in their frequency, levels
of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized foreign
governments, groups and individuals with a wide range of motives and expertise. In addition to extracting or accessing sensitive
information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering
and other means to affect service reliability and threaten the security, confidentiality, integrity and availability of information.
The prevalent use of mobile devices that access sensitive information also increases the risk of data security incidents which
could lead to the loss of confidential information or other intellectual property. While to our knowledge we have not experienced
any material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our
operations or the operations of third-party collaborators, service providers, contractors and consultants, it could result in
a material disruption of our development programs and significant reputational, financial, legal, regulatory, business or operational
harm. The costs to us to mitigate, investigate and respond to potential security incidents, breaches, disruptions, network security
problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have
implemented security measures to protect our data security and information technology systems, our efforts to address these problems
may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm
to our business and our competitive position.
24
Failure
to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement
actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity.
Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use
or adoption, and could otherwise negatively affect our operating results and business.
Regulation
of data processing is evolving, as federal, state, and foreign governments continue to adopt new, or modify existing, laws and
regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. We and our
partners may be subject to current, new, or modified federal, state, and foreign data privacy and protection laws and regulations
(e.g., laws and regulations that address data privacy and data security including, without limitation, health data). These new
or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance
on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing
personal data. These and other requirements could require us or our partners to incur additional costs to achieve compliance,
limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use,
store, transfer, and process data, impact our or our partners’ ability to process or use data in order to support the provision
of our products or services, affect our or our partners’ ability to offer our products and services in certain locations,
or cause regulators to reject, limit or disrupt our clinical trial activities.
Failure to comply with U.S. and international
data privacy and protection laws and regulations could result in government enforcement actions (which could include civil or criminal
penalties, fines or sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results
and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information
with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals’
privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security or privacy,
even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could
harm our business. Compliance with data protection laws may be time-consuming, require additional resources and could result in
increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments
to customers or partners.
Our
relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational
harm, administrative burdens, and diminished profits and future earnings.
Healthcare
providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which
we may obtain marketing approval. Our arrangements with healthcare providers, payors, customers and others may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements
and relationships through which we research, market, sell and distribute any product candidates for which we may obtain marketing
approval. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate.
Risks
Related to Our Reliance on Third Parties
We
have no manufacturing capabilities and depend on other parties for our manufacturing operations. If these manufacturers fail to
meet our requirements and strict regulatory requirements, our product development and commercialization efforts may be materially
harmed.
We
do not own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely, and may
continue to rely, on third-party contract manufacturers to manufacture APIs, drug products and other components of our product
candidates. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates
ourselves.
The manufacturing process for a product
candidate is subject to FDA and foreign regulatory authority review. We, and our suppliers and manufacturers, must meet applicable
manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order
to comply with regulatory standards, such as cGMPs. Securing marketing approval also requires the submission of information about
the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and foreign regulatory authorities.
If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities
for the manufacture of our product candidates. Moreover, we do not control the manufacturing process at our contract manufacturers
and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers
fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply
of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement
with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or
technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may
have difficulty transferring such to another third party. These factors would increase our reliance on such manufacturer or require
us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates.
25
We expect to continue to rely on third-party
manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future,
manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner
consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing
facilities used to produce our products will be subject to periodic review and inspection by the FDA and foreign regulatory authorities,
including for continued compliance with cGMP requirements, quality control, quality assurance and corresponding maintenance of
records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on
commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third
party’s failure to execute on our manufacturing requirements, comply with cGMPs or maintain a compliance status acceptable
to the FDA or foreign regulatory authorities could adversely affect our business in a number of ways, including:
●
an inability to initiate or continue clinical trials of product candidates under development;
●
delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;
●
loss of the cooperation of existing or future collaborators;
●
subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
●
requirements to cease distribution or to recall batches of our product candidates; and
●
in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.
Our contract manufacturers may experience
manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If
our contract manufacturers were to encounter difficulties, our ability to provide our product candidates to patients in preclinical
and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.
We
intend to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not perform
as contractually required or otherwise expected, we may not be able to obtain regulatory approval for our product candidates.
We do not currently, or in the future,
intend to conduct preclinical studies or clinical trials on our own, and instead will rely on third parties, such as contract research
organizations (CROs), medical institutions, clinical investigators and contract laboratories, to assist us with our preclinical
studies and clinical trials. Accordingly, we will have less control over the timing, quality and other aspects of preclinical studies
and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants are not our
employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third
parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources
from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical
studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.
If
we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not
carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical
trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all
events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance
with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The
FDA generally requires preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to
be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results
of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control
will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or
clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial
condition, results of operations and prospects.
26
Risks
Related to Ownership of Our Common Stock
There
is a limited market for our common stock that may make it more difficult to dispose of your stock.
Our
common stock is currently listed on the Nasdaq Capital Market under the symbol “RLMD”. There is a limited trading
market for our common stock. Accordingly, there can be no assurance as to the liquidity of any markets that may develop for our
common stock, the ability of holders of our common stock to sell shares of our common stock, or the prices at which holders may
be able to sell their common stock.
A
sale of a substantial number of shares of our common stock may cause the price of the common stock to decline.
If
our stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock could
fall. These sales also may make it more difficult for us to sell equity or equity-related securities in the future at a time and
price that we deem reasonable or appropriate. Stockholders who have held their shares for at least six months are be able to sell
their shares pursuant to Rule 144 under the Securities Act of 1933, as amended (the Securities Act). We have registered under
separate registration statements in aggregate up to 10,894,658 shares of our common stock for sale into the public market by certain
selling stockholders named therein. These shares represent a large number of shares of our common stock, and if sold in the market
all at once or at about the same time, could depress the market price of our common stock during the period the registration statement
remains effective and could also affect our ability to raise equity capital.
We
are subject to the reporting requirements of federal securities laws, which can be expensive and may divert resources from other
projects, thus impairing our ability grow.
We
are a public reporting company and, accordingly, subject to the information and reporting requirements of the Exchange Act and
other federal securities laws, including compliance with the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). The costs of
preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited
reports to stockholders would cause our expenses to be higher than they would be if we remained privately held.
It
may be time consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required
by the Sarbanes-Oxley Act. We may need to hire additional financial reporting, internal controls and other finance personnel in
order to develop and implement appropriate internal controls and reporting procedures. If we are unable to comply with the internal
controls requirements of the Sarbanes-Oxley Act, then we may not be able to obtain the independent accountant certifications required
by such act, which may preclude us from keeping our filings with the SEC current.
If
we fail to establish and maintain an effective system of internal control, we may not be able to report our financial results
accurately or to prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation
and adversely impact the trading price of our common stock.
Effective
internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial
reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment
existed, and our business and reputation with investors may be harmed. As a result, our small size and any current internal control
deficiencies may adversely affect our financial condition, results of operation and access to capital. We have not performed an
in-depth analysis to determine if historical un-discovered failures of internal controls exist, and may in the future discover
areas of our internal control that need improvement. In addition, as a smaller reporting company, our independent registered
public accounting firm is not required to formally attest to the effectiveness of our internal control over financial reporting
so long as we remain a smaller reporting company, which could increase the likelihood of undiscovered errors in our internal controls
or reported financial statements as compared to issuers whose independent registered public accounting firms have provided such
attestations.
Our
stock price may be volatile.
The
market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors,
many of which are beyond our control, including the following:
●
changes in our industry;
●
competitive pricing
pressures;
●
our ability to obtain
working capital financing;
●
additions or departures
of key personnel;
●
limited “public
float” in the hands of a small number of persons whose sales or lack of sales could result in positive or negative pricing
pressure on the market price for our common stock;
27
●
sales of our common
stock;
●
our ability to execute
our business plan;
●
operating results
that fall below expectations;
●
regulatory developments;
●
economic and other
external factors;
●
period-to-period
fluctuations in our financial results; and
●
inability to develop
or acquire new or needed technology or products.
In
addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market
price of our common stock.
The
Nevada Revised Statutes and our articles of incorporation and bylaws contain provisions that could discourage, delay or prevent
a change in control of our Company, prevent attempts to replace or remove current management and reduce the market price of our
stock.
Provisions
in our articles of incorporation and bylaws may discourage, delay or prevent a merger or acquisition involving us that our stockholders
may consider favorable. For example, our articles of incorporation authorize our board of directors to issue up to 200,000,000
shares of “blank check” preferred stock. As a result, without further stockholder approval, the board of directors
has the authority to attach special rights, including voting and dividend rights, to this preferred stock. With these rights,
preferred stockholders could make it more difficult for a third party to acquire us.
We
are also subject to the anti-takeover provisions of the Nevada Revised Statutes (NRS). Depending on the number of residents in
the state of Nevada who own our shares, we could be subject to the provisions of Sections 78.378 et seq. of the Nevada Revised
Statutes, which, unless otherwise provided in the Company’s articles of incorporation or by-laws, restricts the ability
of an acquiring person to obtain a controlling interest of 20% or more of our voting shares. Our articles of incorporation and
by-laws do not contain any provision which would currently keep the change of control restrictions of Section 78.378 from applying
to us.
In
addition, our articles of incorporation and amended and restated bylaws provide that our board of directors is classified into
three classes of directors with staggered three-year terms. Only one class of directors will be elected at each annual meeting
of stockholders, with the other classes continuing for the remainder of their respective three-year terms. A
third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult
and time consuming for stockholders to replace a majority of the directors on a classified board of directors.
Our
bylaws provides that a Nevada court and the federal district courts of the United States will be the exclusive forum for substantially
all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial
forum for disputes with us or our directors, officers or employees.
Pursuant
to our bylaws, to the fullest extent permitted by law, and unless we consent in writing to the selection of an alternative forum,
the Eighth Judicial District Court of Clark County, Nevada, is the sole and exclusive forum for any stockholder (including a beneficial
owner of stock) to bring (a) any derivative action or proceeding brought in the name or right of the Company or on our behalf,
(b) any action asserting a claim of, or a claim based on, breach of any fiduciary duty owed by any current or former director,
officer, employee, agent or stockholder of the Company to the Company or the Company’s stockholders, (c) any action arising
or asserting a claim arising pursuant to any provision of NRS Chapters 78 or 92A or any provision of the articles of incorporation
or our bylaws or (d) any action asserting a claim against us or any current or former director, officer, employee or stockholder
(including a beneficial owner of stock) governed by the internal affairs doctrine, including, without limitation, any action to
interpret, apply, enforce or determine the validity of our articles of incorporation or bylaws. By its terms, to the fullest extent
permitted by law, our forum selection provision applies to actions arising under the Securities Act or Exchange Act. (However,
Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder, and the Company does not intend for its exclusive forum jurisdiction
provision to apply to Exchange Act claims.) These choice of forum provisions may limit a stockholder’s ability to bring
a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees. If a court
were to find the choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur
additional costs associated with resolving such action in other jurisdictions, which could harm our business.
28
ITEM 1B.
UNRESOLVED STAFF COMMENTS
Not
applicable.
ITEM
2. PROPERTIES
We
do not own any property.
On
January 1, 2019, the Company changed its corporate headquarters to 880 Third Avenue, 12th Floor, New York, New York 10022.
Pursuant to a lease agreement, dated January
1, 2019, and renewed in 2020 the Company leased the space for a total monthly cost of $13,610. For 2021, the lease agreement was
renewed at an average monthly rent rate of approximately $8,730.
Effective
January 1, 2019, the Company terminated its prior lease agreement, dated May 2, 2017, with Regus Management Group, LLC for space
at 750 Third Avenue, 9 th Floor, New York, NY 10017.
On June 8, 2017, the Company entered into
an Amended and Restated License Agreement (the License) with Actinium for office space located at 275 Madison Avenue, 7th Floor,
New York, New York 10016, our former corporate headquarters. This agreement amends and restates the license agreement entered into
between the parties on March 10, 2016. Pursuant to the terms of the License, Actinium will continue to license the furniture, fixtures,
equipment and tenant improvements located in the premises (the FFE). Actinium will pay to the Company a license fee of $7,529 per
month. Actinium shall have at any time during the term of this Agreement the right to purchase the FFE. The term of the License
is contemporaneous with the Lease Agreement.
ITEM
3. LEGAL PROCEEDINGS
From time to time, the Company may become
involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent
uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the
Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually
or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results,
or cash flows.
Lawsuit Brought by Current Employee
On July 15, 2020, an employee of the Company filed
a Complaint alleging unequal pay based on gender and other employment-based claims. The Company intends to defend the lawsuit, it is currently
in discovery and the ultimate outcome is not known.
ITEM
4. MINE SAFETY DISCLOSURES
Not
applicable.
29
PART
II
ITEM
5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market
Information
Our
common stock is listed on NASDAQ, under the symbol “RLMD”.
Holders
As
of December 31, 2020, 16,332,939 shares of common stock were issued and outstanding, which were held by 178 holders of record.
These stockholders held their stock either individually or in nominee or “street” names through various brokerage
firms. There are no shares of Class A convertible preferred stock outstanding. Our transfer agent is:
Empire
Stock Transfer
1859
Whitney Mesa Drive
Henderson,
NV 89014
Telephone
(702) 818-5898
www.empirestock.com
Inquiries
regarding stock transfers, lost certificates or address changes should be directed to the above address.
Dividends
We
plan to retain any earnings for the foreseeable future for our operations. We have never paid any cash dividends on our stock
and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will
be at the discretion of our Board of Directors and will depend on our financial condition, operating results, capital requirements
and such other factors as our Board of Directors deems relevant.
30
Securities
Authorized for Issuance under Equity Compensation Plans
Relmada has a 2014 Option and Equity Incentive
Plan, as amended (the Plan) in which its directors, officers, employees and consultants shall be eligible to participate. The Plan
allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase
shares of the Company. On March 6, 2020, at the annual shareholders meeting, our shareholders approved the increase in shares authorized
to be granted under the Plan by 2,500,000 shares. With these grants and approvals, as of December 31, 2020, the Company had 1,247,205
awards available to be issued.
The
following table summarizes our equity compensation plan information as of December 31, 2020:
Equity Compensation Plan Information
Plan Category
Number of securities to be issued upon exercise of outstanding options and stock appreciation rights
Weighted- average exercise price of outstanding options and stock appreciation rights
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
(a)
(b)
(c)
Equity compensation plans approved by security holders
3,905,737
$ 24.32
1,247,205
Equity compensation plans not approved by security holders
-
-
-
Total
3,905,737
$ 24.32
1,247,205
ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The
information and financial data discussed below is derived from the consolidated financial statements of Relmada for the year ended
December 31, 2020, year ended December 31, 2019 (unaudited), six months ended December 31, 2019 and year ended June 30, 2019.
The consolidated financial statements of Relmada were prepared and presented in accordance with generally accepted accounting
principles in the United States. The information and financial data discussed below is only a summary and should be read in conjunction
with the historical financial statements and related notes of Relmada contained elsewhere in this Report. The consolidated financial
statements contained elsewhere in this Report fully represent Relmada’s financial condition and operations; however, they
are not indicative of the Company’s future performance. See “Cautionary Note Regarding Forward Looking Statements”
above for a discussion of forward-looking statements and the significance of such statements in the context of this Annual Report.
This
discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual
results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those
set forth in the section entitled “ Risk Factors ” and elsewhere herein. The information and financial data discussed
below is only a summary and should be read in conjunction with the historical financial statements and related notes of Relmada
Therapeutics, Inc. contained elsewhere in this document. Relmada’s current consolidated financial position and consolidated
results of operations; are not necessarily indicative of the Company’s future performance. See “Cautionary Note Regarding
Forward Looking Statements” above for a discussion of forward-looking statements and the significance of such statements
in the context of this document.
31
Our
Corporate History and Background
Relmada Therapeutics is a late-stage, publicly
traded biotechnology company developing (New Chemical Entities) NCEs to address areas of high unmet medical need in the treatment
of CNS diseases - primarily depression. The Company’s lead product Esmethadone, is an NCE being developed as a rapidly acting,
oral agent for the treatment of depression and other potential indications. We have previously completed Phase 1 single and multiple
ascending dose studies and on October 15, 2019 we reported top-line data from study REL-1017-202, a double-blind, placebo-controlled
Phase 2 clinical trial evaluating the safety, tolerability and efficacy of two doses of REL-1017, 25 mg once a day and 50 mg once
a day, as an adjunctive treatment in patients with MDD. On Dec. 7, the Company announced that the first patient had been enrolled
in the first Phase 3 clinical trial (RELIANCE I) of REL-1017, as an adjunctive treatment for major depressive disorder (MDD).
Key points of the REL-017 Phase 3 program
agreed upon in discussions with FDA include:
● The Phase 3 program will consist of two
sister, two-arm, placebo-controlled clinical trials. Each trial will be conducted in 55 clinical sites in the United States and
will include approximately 400 MDD patients with inadequate response to standard antidepressants in their current depression episode.
Patients will add either a 25 mg oral dose of REL-1017 once per day or placebo to their ongoing antidepressant treatment.
● The primary endpoint to be evaluated will
be the change from baseline on the Montgomery and Asberg Depression Rating Scale (MADRS) score at day-28 for REL-1017 compared
to placebo. Success on this endpoint with the collection of sufficient safety data would support the use of REL-1017 for chronic
treatment, if approved.
● The change from baseline and the 7-day
MADRS score will serve as a key secondary endpoint and will provide data on the rapid onset of treatment effect; statistically
significant separation between REL-1017 and the control group was achieved by day 4 in the Phase 2 proof-of-principle trial completed
in 2019.
● The Company expects to initiate the second
Phase 3 trial, RELIANCE II, in the first half of 2021. Patients who complete RELIANCE I and RELIANCE II will be eligible to rollover
into the long-term, open-label study, which is also expected to include subjects who had not previously participated in a REL-1017
clinical trial.
The
Company changed its fiscal year end to December 31 from June 30. This transition report was for the six-month transition period
of July 1, 2019 through December 31, 2019. The information for the year ended December 31, 2019 is presented for comparative
purposes only and is unaudited.
We have not generated revenues and do
not anticipate generating revenues for the foreseeable future. We had a net loss of approximately $59,456,400, $15,005,200, $8,196,500,
and $17,318,100 for the years ended December 31, 2020, December 31, 2019 (unaudited), six months ended December 31, 2019, and
for the year ended June 30, 2019, respectively. At December 31, 2020, we have an accumulated deficit of approximately $179,315,300.
Results
of Operations
For
the Year Ended December 31, 2020 vs the Year Ended December 31, 2019 (unaudited)
Research
and Development Expense
Total research and development expense for the year ended December
31, 2020 was approximately $35,972,700, as compared to $7,859,500 for the same period of 2019, an increase of $28,113,200. The
increase in research and development expense was primarily due to:
●
Increase in study costs of $15,238,700 associated with the execution of our Phase 2 and Phase 3 studies;
●
Increase in manufacturing and drug storage costs of $989,700;
●
Increase in pre-clinical and toxicology expenses of $1,881,900;
●
Increase in compensation expense of $2,376,000 related to the hiring of six additional research and development employees and their related bonuses;
●
Increase in stock-based compensation expense of $3,677,600 of stock-based compensation expense related to the hiring of six additional research and development employees and the related options granted to them, as well as the separation agreement with Ottavio Vitolo of approximately $1,500,000;
●
Increase in other research expenses of $3,949,400 primarily associated to the additional consultants contracted with to assist in the execution of our Phase 3 studies.
32
General
and Administrative Expense
Total general and administrative expense
for the year ended December 31, 2020 was approximately $24,865,900, as compared to $7,249,900 for the same period of 2019, an
increase of $17,616,000. The increase in general and administrative expenses was primarily due to:
●
Increase in compensation expense of $2,753,800 related to the hiring of four additional general and administrative employees and their related bonuses;
●
Increased in stock-based compensation expense of $13,934,400 primarily related to options granted to employees and the board of directors during 2020;
●
Increase in other G&A expenses of $927,800.
Interest
Income and Expense, Net
Interest income and realized and unrealized
gains and losses in investments was approximately $1,382,300 and $104,100 for the years ended December 31, 2020 and 2019, respectively.
The increase of $1,278,200 resulted from the increase in investments during 2020 compared to 2019.
Income Taxes
The Company did not provide for income
taxes for the year ended December 31, 2020 and December 31, 2019, since there was a loss and a full valuation allowance against
all deferred tax assets.
Net Loss
The Company recorded a net loss of approximately $59,456,400
and $15,005,200 or $3.81 and $1.62 per common share, basic and diluted, during the years ended December 31, 2020 and 2019, respectively,
based on the factors described above.
Liquidity
As shown in the accompanying financial statements, the Company
incurred negative operating cash flows of $27,808,801 for the year ended December 31, 2020 and has an accumulated deficit of $179,315,303
from inception through December 31, 2020.
Relmada has funded its past operations
through equity raises and most recently in the year ended December 31, 2020, Relmada raised net proceeds from the sale of common
stock of $19,791,644 and $8,056,416 through the exercise of warrants, and $735,514 through the exercise of options.
Management believes that due to the recent equity raises completed
and exercises of outstanding warrants and the resulting cash position on its balance sheet, it has obtained sufficient funding
to continue ongoing operations for at least 12 months from the filing of this annual report. Since December 31, 2020 and to date,
the Company has received approximately $1,909,200 in warrant and option exercises, which resulted in the Company having approximately
$105.3 million in cash, cash equivalents and short term investments at March 15, 2021. Based on its budgeted cash flow requirements,
the Company believes these funds are sufficient to fund its ongoing operations for at least 12 months after the filing of this
annual report. The Company expects that the cash burn rate for the 12 months ended December 31, 2021, will range between $75 and
$100 million.
The
following table sets forth selected cash flow information for the periods indicated below:
(Unaudited)
For the
Year Ended
For the
Year Ended
For the
Six Months Ended
For the
Year Ended
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Cash used in operating activities
$ (27,808,801 )
$ (12,092,784 )
$ (6,413,775 )
$ (10,497,854 )
Cash used in investing activities
(34,447,648 )
(80,164,823 )
(80,164,823 )
-
Cash provided by financing activities
28,473,327
126,109,375
113,640,563
17,475,465
Net increase/(decrease) in cash and cash equivalents
$ (33,783,122 )
$ 33,851,768
$ 27,061,965
$ 6,977,611
For the year ended December 31, 2020, cash
used in operating activities was $27,808,801 primarily due to the net loss of $59,456,394. This was offset by non-cash expenses
which primarily consisted of stock-based compensation of $20,777,272. There were realized losses and unrealized gains on short
term investments of $156,213 and $139,267, respectively. In addition, there were changes in operating assets and liabilities for
the year ended December 31, 2020 of $10,849,623.
For the unaudited year ended December 31, 2019, cash used in
operating activities was $12,092,784 primarily due to the net loss of $15,005,199. This was offset by non-cash expenses which primarily
consisted of stock-based compensation and loss on fair value of shares relinquished of $3,165,153 and $394,410, respectively. There
were changes in operating assets and liabilities for the year ended December 31, 2020 of $137,309.
For the six months ended December 31, 2019,
the transition period, cash used in operating activities was $6,413,775 primarily due to the net loss of $8,196,542. This was offset
by non-cash expenses which primarily consisted of stock-based compensation of $2,367,001. There were changes in operating assets
and liabilities for the six months ended December 31, 2019 of $586,434.
33
For the year ended June 30, 2019 cash used
in operating activities was $10,497,854 primarily due to the net loss of $17,318,060. This was offset by non-cash expenses which
primarily consisted of stock-based compensation of $1,213,996, the change in the fair value of derivative liabilities of $54,634,
loss on fair value of shares relinquished of $394,410, loss on extinguishment of promissory note of $3,774,468 and amortization
of deferred financing costs of $661,168. There were changes in operating assets and liabilities for the years ended June 30, 2019
of $1,505,480.
For the year ended December 31, 2020, cash
used in investing activities was $34,447,648, due to $182,051,630 of purchases of short term investments offset by $147,603,982
of sales of short term investments.
For the unaudited year ended December 31,
2019, cash used in investing activities was $80,164,823, due to $84,849,198 of purchases of short term investments offset by $4,684,375
of sales of short term investments.
For the six months ended December 31, 2019,
cash used in investing activities was $80,164,823, due to $84,849,198 of purchases of short term investments offset by $4,684,375
of sales of short term investments.
For the year ended June 30, 2019, no cash
was used in investing activities.
Net cash provided by financing activities for the six months
ended December 31, 2020, was $28,473,327 due to proceeds from issuance of common stock of $19,791,644, proceeds from warrants exercised
for common stock of $8,056,416, proceeds from options exercised for common stock of $735,514 partially offset by payments of notes
payable of $110,247.
Net cash provided by financing activities
for the unaudited year ended December 31, 2019, was $126,109,375 due to proceeds from issuance of common stock of $122,031,032,
proceeds from warrants exercised for common stock of $4,447,038 partially offset by payments of notes payable of $368,695.
Net cash provided by financing activities
for the six months ended December 31, 2019, was $113,640,563 due to proceeds from issuance of common stock of $109,447,482, proceeds
from warrants exercised for common stock of $4,447,038 partially offset by payments of notes payable of $253,957.
Net cash provided by financing activities
for the year ended June 30, 2019 was $17,475,465 due to proceeds from issuance of common stock of $17,760,635 partially offset
by payments of notes payable of $285,170.
Effects
of Inflation
Our
assets are primarily monetary, consisting of cash and cash equivalents. Because of their liquidity, these assets are not directly
affected by inflation. Because we intend to retain and continue to use our equipment, we believe that the incremental inflation
related to replacement costs of such items will not materially affect our operations. However, the rate of inflation affects our
expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate
at which we use our resources.
Contractual
Obligations
The
following tables sets forth our contractual obligations for the next five years and thereafter:
Total
Less than
1 year
1 - 2 years
3 - 5 years
More than
5 years
Office lease
$ 104,760
$ 104,760
$ -
$ -
$ -
Total obligations
$ 104,760
$ 104,760
$ -
$ -
$ -
Off-Balance
Sheet Arrangements
We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to investors.
Seasonality
We
do not have a seasonal business cycle.
Critical
Accounting Policies and Use of Estimates
The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
for the reporting period. Actual results could differ from those estimates. The significant estimates are incurred costs of clinical
studies, stock-based compensation expense, valuation of derivative financial liabilities, and income taxes and valuation of deferred
tax assets.
34
Research
and Development
Research and development costs primarily consist of research contracts
for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all
research and development costs in the period incurred.
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange
for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes
option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to
non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued,
whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value
at the end of each reporting period until such warrants vest, and the fair value of such instruments, as adjusted, is expensed
over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon
the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and
the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the
Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased.
Income
Taxes
The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. As of December 31, 2020 and 2019, and June 30, 2019, the Company
recorded a valuation allowance to the full extent of our net deferred tax assets since the likelihood of realization of the benefit
does not meet the more likely than not threshold.
Recent
Accounting Pronouncements
The
Company lists material recent accounting pronouncements in Note 2 of the consolidated financial statements.
35
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest
rate risk
Our
cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. Our cash equivalents
are in a money market account. Because of the short-term maturities of our cash and cash equivalents, we do not believe that an
increase in market rates would have a significant impact on the realized value of our investments. We place our cash and cash
equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation limits coverage
for all depository accounts. Our cash and cash equivalents at times may exceed covered limits.
Foreign
currency exchange risk
We
currently have limited, but may in the future have increased, clinical and commercial manufacturing agreements which are denominated
in Euros or other foreign currencies. As a result, our financial results could be affected by factors such as a change in the
foreign currency exchange rate between the U.S. dollar and the Euro or other applicable currencies, or by weak economic conditions
in Europe or elsewhere in the world. We are not currently engaged in any foreign currency hedging activities.
Market
indexed security risk
We
have issued warrants to various holders underlying shares of our common stock. These warrants are re-measured to their fair value
at each reporting period with changes in their fair value recorded as derivative gain (loss) in the accompanying consolidated
statement of operations. We use the Black-Scholes model for valuation of the warrants.
ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Our
audited consolidated financial statements as of December 31, 2020 and for the year then ended, as of December 31, 2019 and for
the six months then ended, as of June 30, 2019 and for the year then ended and our unaudited financial statements for the year
ended December 31, 2019 are included beginning on Page F-1 immediately following the signature page to this report. See Item 15
for a list of the financial statements included herein.
ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A .
CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
Under
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer,
we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief
Financial Officer has concluded that, at December 31, 2020, such disclosure controls and procedures were effective.
Disclosure
controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed
in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure
that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated
to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as
appropriate, to allow timely decisions regarding required disclosure.
Limitations
on the Effectiveness of Controls
Our
disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure
control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that all control issues, if any, within a company have been detected. Our Chief Executive Officer and Chief Financial
Officer has concluded, based on his evaluation as of the end of the period covered by this Report that our disclosure controls
and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.
Changes
in Internal Control Over Financial Reporting
There
were no changes in the Company’s internal controls over financial reporting that occurred during the fourth quarter of the
fiscal year covered by this Annual Report on Form 10-K that have materially affected, or are reasonably likely to materially affect,
the Company’s internal control over financial reporting.
36
Management’s
Report on Internal Control Over Financial Reporting
As
required by the SEC rules and regulations for the implementation of Section 404 of the Sarbanes-Oxley Act, our management
is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over
financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of our consolidated financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial
reporting includes those policies and procedures that:
(1)
pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions
of the assets of our company,
(2)
provide
reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements
in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures
are being made only in accordance with authorizations of our management and directors, and
(3)
provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets
that could have a material effect on the consolidated financial statements.
Because
of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our
consolidated financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk
that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures
may deteriorate. Management assessed the effectiveness of our internal control over financial reporting at December 31, 2020.
In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway
Commission COSO (2013 framework). Based on our assessments and those criteria, management determined that we did maintain effective
internal control over financial reporting at December 31, 2020.
ITEM 9B.
OTHER INFORMATION
On March 19, 2021, our Board of Directors
unanimously approved, subject to stockholder approval, the Company’s 2021 Equity Incentive Plan (the “2021 Plan”),
pursuant to which awards covering up to 1,500,000 shares of our common stock will be available for issuance.
The purpose of the 2021 Plan is to (a)
enable the Company and its affiliates to attract and retain the types of employees, directors and consultants who will contribute
to the Company’s long range success; (b) provide incentives that align the interests of employees, consultants and directors
with those of the stockholders of the Company; and (c) promote the success of the Company’s business, thus enhancing the
value of the Company for the benefit of its stockholders.
Administration. The 2021 Plan will be administered
by a committee (the “Committee”), or in the Board’s sole discretion by the Board. In case no Committee has been
appointed, the Board may appoint one or more members of the Board appointed by the Board to administer the 2021 Plan in accordance
with the terms of the 2021 Plan. The Board has appointed the Compensation Committee of the Board to administer the 2021 Plan.
Shares Available for Awards. Subject to
adjustment in certain circumstances in accordance with the terms of the 2021 Plan, we will reserve for issuance under the 2021
Plan no more than 1,500,000 shares of common stock (subject to adjustment in certain circumstances as provided in the Plan). Shares
of Common Stock available for distribution under the 2021 Plan may consist, in whole or in part, of authorized and unissued shares,
treasury shares or shares reacquired by the Company in any manner. Shares of Common Stock subject to an award that expires or is
canceled, forfeited, or terminated without issuance of the full number of shares of Common Stock to which the award related, as
well as any shares of common stock subject to an award that are (a) tendered in payment of an option, (b) delivered or withheld
by the company to satisfy any tax withholding obligation, or (c) covered by a stock-settled stock appreciation right or other awards
that were not issued upon the settlement of the award, shall be added back to the shares of common stock available for issuance
of awards or delivery under the 2021 Plan.
Available Awards. Awards that may be granted
under the 2021 plan include: (a) incentive stock options, (b) non-qualified stock options, (c) stock appreciation rights, (d) restricted
awards, (e) performance share awards, (f) cash awards, and (g) other equity-based awards.
Recipients of Grants. Incentive stock options
may be granted only to employees. Awards other than incentive stock options may be granted to employees, consultants and directors
and those individuals whom the Committee or the Board determines are reasonably expected to become employees, consultants and directors
following the grant date. Our principal executive officer, principal financial officer and other named executive officers are eligible
to participate in and receive awards under the 2021 Plan.
Term. The 2021 Plan has a term of ten years.
This summary of the 2021 Plan is qualified
in its entirety by the full text of the 2021 Plan, which is filed as Exhibit 10.61 to this Report and is incorporated by reference
herein.
The 2021 Plan will be submitted for the approval of our stockholders
at our 2020 Annual Meeting of Stockholders. If the proposal is not approved by the stockholders, the 2021 Plan will not be effective.
37
PART
III
The information required for the Items
contained in Part III are incorporated herein by reference from our definitive proxy statement for our 2021 Annual Meeting
of Stockholders (the “Proxy Statement”), which will be filed with the SEC no later than 120 days after December 31,
2020.
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE
ITEM
11. EXECUTIVE COMPENSATION
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES
38
PART
IV
ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Financial
Statement Schedules
Our
consolidated financial statements are listed on the Index to Financial Statements on this annual report on Form 10-K beginning
on page F-1.
All
financial statement schedules are omitted because they are not applicable or the required information is shown in the financial
statements or notes thereto.
39
RELMADA
THERAPEUTICS, INC.
(INDEX
TO FINANCIAL STATEMENTS)
Page
Report
of Independent Registered Public Accounting Firm
F-2
Consolidated
Balance Sheets as of December 31, 2020 and 2019 and June 30, 2019
F-3
Consolidated
Statements of Operations for the Years Ended December 31, 2020, and 2019 (unaudited), Six Months Ended December 31, 2019 and
for the Year Ended June 30, 2019
F-4
Consolidated
Statements of Stockholders’ Equity (Deficit) for the Year Ended December 31, 2020, Six Months Ended December 31, 2019
and for the Year Ended June 30, 2019
F-5
Consolidated
Statements of Stockholders’ Equity (Deficit) for the Year Ended December 31, 2019 (unaudited)
Consolidated
Statements of Cash Flows for the Years Ended December 31, 2020 and 2019 (unaudited), the Six Months Ended December 31, 2019
and for the Year Ended June 30, 2019
F-6
Notes
to Consolidated Financial Statements
F-8
F- 1
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
Relmada Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated
balance sheets of Relmada Therapeutics, Inc. (the “Company”) as of December 31, 2020, December 31, 2019 and June 30, 2019,
, the related consolidated statements of operations, stockholders’ equity and cash flows for the year ended December 31, 2020, the
six months ended December 31, 2019 and the year ended June 30, 2019, and the related notes (collectively referred to as the “financial
statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2020, December 31, 2019, and June 30, 2019, and the results of its operations and its cash flows for year ended December
31, 2020, the six months ended December 31, 2019 and the year ended June 30, 2019, in conformity with accounting principles generally
accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a
matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit
committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion
on the critical audit matter or on the accounts or disclosures to which it relates.
Valuation and accounting for stock-based compensation
Description of the Matter
As described in Notes 8 and 11 to the financial statements,
the Company awarded a total of 1,000,000 options to employees and 250,000 warrants to nonemployees during 2020. The Company also entered
into Separation and Severance Agreements with two employees during the year ended December 31, 2020 and agreed to accelerate the vesting
period of their options. The Company recognized an aggregate stock-based compensation of $20.8 million during the year ended December
31, 2020, which includes the above instruments.
Auditing management’s valuation and accounting
for stock-based compensation required subjective judgement to analyze the terms within the stock-based agreements to determine that we
concurred with management’s valuation and calculations.
How We Addressed the Matter in Our Audit
Our audit procedures included, amongst others:
We tested the option and warrant agreements to determine
whether management appropriately evaluated such agreements on the date of grant.
We reviewed the vesting terms of the option and warrant
agreements to determine the stock-based compensation is recorded in the proper period.
We reviewed the terms of the Separation and Severance Agreements to determine
that any modifications related to the options thereto were appropriately recorded.
We tested the underlying expenses and other information
that served as the basis for valuation and tested inputs and terms used in the valuation to determine completeness and accuracy.
We evaluated the reasonableness of the valuation
method and assumptions used by management to calculate the values on the date of grant by developing an independent estimate of the volatility
by utilizing third party historical data of closing prices.
/s/ Marcum llp
Marcum llp
We have served as the Company’s auditor since 2014.
Houston, Texas
March 24, 2021
F- 2
Relmada
Therapeutics, Inc.
Consolidated
Balance Sheets
As of
As of
As of
December 31,
December 31,
June 30,
2020
2019
2019
Assets
Current assets:
Cash and cash equivalents
$ 2,495,397
$ 36,278,519
$ 9,216,554
Short-term investments
114,595,525
80,164,823
-
Other receivable
-
-
176,980
Lease payments receivable – short term
79,457
73,091
70,102
Prepaid expenses
903,190
423,863
520,745
Total current assets
118,073,569
116,940,296
9,984,381
Fixed assets, net of accumulated depreciation
1,258
5,010
7,210
Other assets
25,000
25,000
25,000
Lease payments receivable – long term
86,377
165,834
203,142
Total assets
$ 118,186,204
$ 117,136,140
$ 10,219,733
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$ 8,346,475
$ 522,663
$ 924,359
Accrued expenses
4,256,983
824,936
1,317,855
Notes payable
-
110,247
364,204
Total current liabilities
12,603,458
1,457,846
2,606,418
Total liabilities
12,603,458
1,457,846
2,606,418
Stockholders’ Equity:
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding
-
-
-
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding
-
-
-
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,332,939, 14,457,013 and 9,744,643 shares issued and outstanding, respectively
16,333
14,457
9,744
Additional paid-in capital
284,881,716
235,522,746
119,265,938
Accumulated deficit
(179,315,303 )
(119,858,909 )
(111,662,367 )
Total stockholders’ equity
105,582,746
115,678,294
7,613,315
Total liabilities and stockholders’ equity
$ 118,186,204
$ 117,136,140
$ 10,219,733
The
accompanying notes are an integral part of these consolidated financial statements.
F- 3
Relmada
Therapeutics, Inc.
Consolidated
Statements of Operations
(Unaudited)
Year
Year
Six months
Year
Ended
ended
ended
ended
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Operating expenses:
Research and development
$ 35,972,731
$ 7,859,453
$ 3,513,606
$ 7,024,747
General and administrative
24,865,942
7,249,858
4,757,999
5,703,173
Total operating expenses
60,838,673
15,109,311
8,271,605
12,727,920
Loss from operations
(60,838,673 )
(15,109,311 )
(8,271,605 )
(12,727,920 )
Other income (expenses):
Change in fair value of derivative liabilities
-
-
-
(54,634 )
Interest income (expense), net
1,399,225
104,112
75,063
(761,038 )
Realized loss on short-term investments
(156,213 )
-
-
-
Unrealized gain on short-term investments
139,267
-
-
-
Loss on extinguishment of debt
-
-
-
(3,774,468 )
Total other income (expenses), net
1,382,279
104,112
75,063
(4,590,140 )
Net loss
$ (59,456,394 )
$ (15,005,199 )
$ (8,196,542 )
$ (17,318,060 )
Net loss per common share – basic and diluted
$ (3.81 )
$ (1.62 )
$ (0.77 )
$ (2.74 )
Weighted average number of common shares outstanding – basic and diluted
15,594,228
9,241,219
10,577,866
6,311,769
The
accompanying notes are an integral part of these consolidated financial statements.
F- 4
Relmada
Therapeutics, Inc.
Consolidated
Statements of Stockholders’ Equity (Deficit)
Common Stock
Additional Paid-in
Accumulated
Shares
Par Value
Capital
Deficit
Total
Balance at June 30, 2018
3,137,468
$ 3,137
$ 88,828,094
$ (94,344,307 )
$ (5,513,076 )
Cumulative effect of Write-off of Derivative Liabilities under ASU 2017-11
-
-
59,397
-
59,397
Adjusted Balance at June 30, 2018
3,137,468
3,137
88,887,491
(94,344,307 )
(5,453,679 )
Stock-based compensation expense
-
-
1,213,996
-
1,213,996
Conversion of notes and accrued interest
2,682,917
2,683
11,802,150
-
11,804,833
Equity units issued for cash, net
3,975,115
3,975
17,756,660
-
17,760,635
Shares relinquished by former officer
(75,848 )
(76 )
(394,334 )
-
(394,410 )
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder
24,991
25
(25 )
-
-
Net loss
-
-
-
(17,318,060 )
(17,318,060 )
Balance – June 30, 2019
9,744,643
9,744
119,265,938
(111,662,367 )
7,613,315
Stock-based compensation expense
-
-
2,367,001
-
2,367,001
Equity units issued for cash, net
3,951,299
3,951
109,443,531
-
109,447,482
Warrants exercised
656,943
657
4,446,381
-
4,447,038
Cashless exercise of warrants
42,644
43
(43 )
-
-
Cashless exercise of options
61,484
62
(62 )
-
-
Net loss
-
-
-
(8,196,542 )
(8,196,542 )
Balance – December 31, 2019
14,457,013
14,457
235,522,746
(119,858,909 )
115,678,294
Stock-based compensation expense
-
-
20,777,272
-
20,777,272
Equity offering, net
427,700
428
19,791,216
-
19,791,644
Warrants exercised
1,159,989
1,160
8,055,256
-
8,056,416
Cashless exercise of warrants
42,475
42
(42 )
-
-
Options exercised
155,558
156
735,358
-
735,514
Cashless exercise of options
90,204
90
(90 )
-
-
Net loss
-
-
-
(59,456,394 )
(59,456,394 )
Balance – December 31, 2020
16,332,939
$ 16,333
$ 284,881,716
$ (179,315,303 )
$ 105,582,746
The
accompanying notes are an integral part of these consolidated financial statements.
F- 5
Relmada
Therapeutics, Inc.
Consolidated
Statements of Cash Flows
(Unaudited)
Year
Year
Six months
Year
ended
ended
ended
ended
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Cash flows from operating activities
Net loss
$ (59,456,394 )
$ (15,005,199 )
$ (8,196,542 )
$ (17,318,060 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
3,752
4,363
2,200
4,870
Stock-based compensation
20,777,272
3,165,153
2,367,001
1,213,996
Realized loss on short-term investments
156,213
-
-
-
Unrealized gain on short-term investments
(139,267 )
-
-
-
Amortization of deferred financing costs
-
-
-
661,168
Change in fair value of derivative liabilities
-
-
-
54,634
Fair value of shares relinquished
-
(394,410 )
-
(394,410 )
Loss on promissory note extinguishment
-
-
-
3,774,468
Changes in operating assets and liabilities:
Prepaid expenses and other assets
(479,327 )
471,912
96,882
270,167
Other receivable
-
-
176,980
(169,363 )
Lease payment receivable
73,091
67,235
34,319
64,486
Accounts payable
7,823,812
163,773
(401,696 )
158,920
Accrued expenses
3,432,047
(565,611 )
(492,919 )
1,181,270
Net cash used in operating activities
(27,808,801 )
(12,092,784 )
(6,413,775 )
(10,497,854 )
Cash flows from investing activities
Purchase of investments
(182,051,630 )
(84,849,198 )
(84,849,198 )
-
Sale of investments
147,603,982
4,684,375
4,684,375
-
Net cash used in investing activities
(34,447,648 )
(80,164,823 )
(80,164,823 )
-
Cash flows from financing activities
Proceeds from issuance of common stock, net of fees
19,791,644
122,031,032
109,447,482
17,760,635
Proceeds from warrants exercised for common stock
8,056,416
4,447,038
4,447,038
-
Proceeds from options exercised for common stock
735,514
-
-
-
Principal payment of notes payable
(110,247 )
(368,695 )
(253,957 )
(285,170 )
Net cash provided by financing activities
28,473,327
126,109,375
113,640,563
17,475,465
Net increase/(decrease) in cash and cash equivalents
(33,783,122 )
33,851,768
27,061,965
6,977,611
Cash and cash equivalents at beginning of the period
36,278,519
2,426,751
9,216,554
2,238,943
Cash and cash equivalents at end of the period
$ 2,495,397
$ 36,278,519
$ 36,278,519
$ 9,216,554
F- 6
Relmada
Therapeutics, Inc.
Consolidated
Statements of Cash Flows (continued)
(Unaudited)
Year
Year
Six months
Year
ended
ended
ended
ended
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Supplemental disclosure of cash flows information:
Cash paid during the period for:
Income taxes
$ -
$ -
$ -
$ -
Interest
$ 2,415
$ 9,034
$ 4,610
$ 5,933
Non-cash investing and financing transactions:
Notes payable issued in connection with director and officer insurance policies
$ -
$ 364,204
$ -
$ 364,204
Cashless exercise of warrants for common stock
$ 42
$ 68
$ 43
$ 25
Cashless exercise of options for common stock
$ 90
$ 62
$ 62
$ -
Write off for derivative liability due to adoption of ASU 2017-11
$ -
$ -
$ -
$ 59,397
Conversion of promissory notes and accrued interest to common stock
$ -
$ -
$ -
$ 8,030,365
The
accompanying notes are an integral part of these consolidated financial statements.
F- 7
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
NOTE
1 - BUSINESS
Relmada Therapeutics Inc. (Relmada, the
Company) (a Nevada corporation) is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone
(d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. esmethadone is a New Chemical Entity
(NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and
other disorders.
On
October 7, 2019, our application to list our common stock on the NASDAQ Capital Market was approved. On October 10, 2019, our
common stock began trading on Nasdaq under our existing symbol, “RLMD.”
On December 19, 2019, the Board of Directors
of the Company approved a change to its end of fiscal year from June 30 to December 31. The change in fiscal year was effective
for the Company’s 2020 fiscal year.
In
addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research
and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject
to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements,
development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary
technology, and compliance with the Food and Drug Administration (FDA) and other governmental regulations and approval requirements.
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation and Principles of Consolidation
The
accompanying consolidated financial statements and related notes have been prepared in accordance with accounting principles generally
accepted in the United States of America (U.S. GAAP). The consolidated financial statements include the Company’s accounts
and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated
in consolidation.
On
September 26, 2019, the Company’s Board of Directors approved a 1-to-4 reverse split of the Common Stock, which was effective
on the NASDAQ Capital Market on September 30, 2019. As a result of the reverse stock split, every 4 shares of issued and outstanding
common stock were converted into 1 share of issued and outstanding common stock, with all fractional shares rounded up to the
nearest whole share, and the Company’s authorized share of common stock were reduced from 200,000,000 to 50,000,000 shares.
All share and per share amounts have been retroactively restated to reflect this reverse stock split.
Change
in Fiscal Year
The
Company changed its fiscal year end to December 31 from June 30. The information for the year ended December 31, 2019 is
presented for comparative purposes only and is unaudited.
Liquidity
As shown in the accompanying financial
statements, the Company incurred negative operating cash flows of $27,808,801 for the year ended December 31, 2020 and has an accumulated
deficit of $179,315,303 from inception through December 31, 2020.
Relmada has funded its past operations
through equity raises and most recently in the year ended December 31, 2020, Relmada raised net proceeds from the sale of common
stock of $19,791,644, $8,056,416 through the exercise of warrants and $735,514 through the exercise of options.
Management believes that due to the recent
equity raises completed and exercises of outstanding warrants and the current cash position on its balance sheet, it has obtained
sufficient funding to continue ongoing operations for at least 12 months from the issuance of this annual report. Since December
31, 2020 and to date, the Company has received approximately $1,909,200 in warrant and option exercises, which resulted in the
Company having approximately $105.3 million in cash, cash equivalents, and short term investments at March 15, 2021. Based on
its budgeted cash flow requirements, the Company believes these funds are sufficient to fund its ongoing operations for at least
12 months after the issuance of these consolidated financial statements. Regardless of the results of any ongoing clinical trial,
the Company has control over its expenditures and has the ability to adjust spending accordingly based on the budgeted cash flow
requirements developed and the excess cash on hand.
Management believes that their existing
cash and cash equivalents will enable them to fund operating expenses and capital expenditure requirements for at least the next
12 months from the issuance of these consolidated financial statements. Beyond that point management will evaluate the size and
scope of any subsequent trials that will affect the timing of additional financings through public or private sales of equity or
debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements. Any such expenditures
related to any subsequent trials will not be incurred until such additional financing is raised. Further, additional financing
related to subsequent trials does not affect the Company’s conclusion that based on the cash on hand and the budgeted cash
flow requirements, the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these consolidated
financial statements.
F- 8
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those
estimates. The significant estimates are stock-based compensation expenses, the valuation of derivative liabilities and recorded
amounts related to income taxes.
Cash
and Cash Equivalents
The Company considers cash deposits and
all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s
cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits of $2,495,397 at December
31, 2020 at these institutions exceed federally insured limits.
Short-term
Investments
The
Company’s investments consist entirely of mutual funds. The securities are measured at fair value based on the net asset
value (“NAV”). The Company has adopted FASB ASU 2016-01, Financial Instruments, for the year ended December 31, 2020
which requires substantially all equity investments in nonconsolidated entities to be measured at fair value with recurring changes
recognized in earnings, except for those accounted for using equity method accounting. Changes in fair value of the securities
are recorded as part of other income on the consolidated statement of operations. Short term investment activity is presented
in the investing activities section on the consolidated statement of cash flows.
Short-term
investments at December 31, 2020 consisted of mutual funds with a fair value of $114,595,525.
Patents
Costs
related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred
since recoverability of such expenditures is uncertain.
Fixed
Assets
Fixed
assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is
calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated
useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.
Leases
The
Company recognizes their leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease
liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line
lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating leases
for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases.
Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term
lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option
to purchase the underlying asset that the lessee is reasonably certain to exercise.
F- 9
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
Fair
Value of Financial Instruments
The
Company’s financial instruments primarily include cash, short term investments derivative liabilities and accounts payable.
Due to the short-term nature of cash and accounts payable the carrying amounts of these assets and liabilities approximate their
fair value. Derivatives are recorded at fair value at each period end.
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly
transaction between market participants at the reporting date. A fair value hierarchy has been established for valuation inputs
that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority
to unobservable inputs. The fair value hierarchy is as follows:
Level
1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability
to access at the measurement date.
Level
2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly
or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset
or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally
from or corroborated by market data by correlation or other means.
Level
3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable
(supported by little or no market activity).
The
Company’s short-term investment instruments of $114,595,525 at December 31, 2020 are classified using Level 1 inputs
within the fair value hierarchy because they are valued using NAV. Unrealized gains and losses are recorded in the consolidated
statement of operations as unrealized gain on short-term investments. The Company recorded an unrealized gain of $139,267, included
in other income for the period ended December 31, 2020.
Fair
Value on a Recurring Basis
As required by Accounting Standard Codification
(ASC) Topic No. 820 - 10 Fair Value Measurement , financial assets and liabilities are classified based on the lowest level
of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular
input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities
and their placement within the fair value hierarchy levels.
F- 10
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
Income
Taxes
The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. At December 31, 2020 and 2019 and June 30, 2019, the Company had
recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization
of the benefit does not meet the more likely than not threshold.
The Company files a U.S. Federal income
tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for
unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general
and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at
December 31, 2020 and 2019, and June 30, 2019. The open tax years, subject to potential examination by the applicable taxing authority,
for the Company are from June 30, 2018 forward.
Research
and Development
Research
and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits,
stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The
Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including
the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount
expensed and the related prepaid asset and accrued liability.
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange
for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes
option pricing model adjusted for the unique characteristics of those instruments.
Net
Loss per Common Share
Basic
net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders
by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents.
Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common
stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock
method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted
stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of
shares used to calculate basic and diluted shares outstanding due to the Company’s net losses in each period.
F- 11
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
The
potentially dilutive securities that would be anti-dilutive due to the Company’s net loss are not included in the calculation
of diluted net loss per share attributable to common stockholders. The anti-dilutive securities are as follows (in common stock
equivalent shares):
Year ended
December 31,
(Unaudited)
Year ended
December 31,
Six Months
ended
December 31,
Year ended
June 30,
2020
2019
2019
2019
Common stock warrants
2,670,633
3,646,872
3,646,872
4,429,982
Common stock options
3,905,737
3,615,602
3,615,602
1,473,314
Total
6,576,370
7,262,474
7,262,474
5,903,296
Recent
Accounting Pronouncements
In
December 2019, the FASB issued ASU 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ,”
which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to
the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance
is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption
permitted. We do not expect the adoption of ASU 2019-12 to have a material impact on our consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Fair
Value Measurement – Disclosure Framework (Topic 820). The updated guidance improves the disclosure requirements
on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard
disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company
adopted this standard effective January 1, 2020 and the standard did not have a significant impact on the Company’s financial
statements.
In November 2018, FASB issued ASU 2018-18
– Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which,
among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted
for under Topic 606. The amendments in the ASU are effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020 and the standard did
not have a significant impact on the Company’s financial statements.
NOTE
3 - PREPAID EXPENSES
Prepaid
expenses consisted of the following (rounded to nearest $00):
December 31,
2020
December 31,
2019
June 30,
2019
Insurance
$
527,600
$
223,600
$
451,500
Research and Development
291,800
139,200
-
Legal
11,000
11,000
7,500
Other
72,800
50,100
61,800
Total
$
903,200
$
423,900
$
520,800
F- 12
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
NOTE
4 - FIXED ASSETS
Fixed
assets consisted of the following (rounded to nearest $00):
Useful lives
December 31,
2020
December 31,
2019
June 30,
2019
Computer and software
3 years
$ 16,700
$ 16,700
$ 16,700
Less: accumulated depreciation
(15,400 )
(11,700 )
(9,500 )
Fixed assets, net
$ 1,300
$ 5,000
$ 7,200
NOTE
5 - ACCRUED EXPENSES
Accrued
expenses consisted of the following (rounded to nearest $00):
December 31,
2020
December 31,
2019
June 30,
2019
Research and development
$ 2,183,800
$ 134,500
$ 563,400
Professional fees
150,900
172,900
98,400
Accrued bonus
1,444,900
50,000
-
Accrued vacation
351,200
124,600
96,700
Legal Settlement
-
250,000
500,000
Other
126,200
92,900
59,400
Total
$ 4,257,000
$ 824,900
$ 1,317,900
F- 13
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
NOTE
6 - NOTES PAYABLE
In
June 2019, the Company entered into a note for approximately $364,200 in conjunction with a renewal of its director and officer
insurance policy. The interest rate was 3.09% per annum. The note matured on April 9, 2020.
In
June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer
insurance policy. The interest rate was 2.35% per annum. The note matured on April 9, 2019 and was repaid.
At
December 31, 2020 and 2019 and June 30, 2019, the note payable outstanding balances were approximately $0, $110,200, and $364,200,
respectively.
NOTE
7 - DERIVATIVE LIABILITIES
ASC Topic No. 815 – “ Derivatives
and Hedging” provides guidance on determining what types of instruments or embedded features in an instrument issued
by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope
exception in the pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible
preferred instruments issued by the Company.
Until
October 18, 2018, the Company had promissory notes with a redemption feature that was not clearly and closely related to the host
instrument and therefore was considered an embedded derivative which was bifurcated and recorded as a derivative liability. In
determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used
in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature.
On
October 12 and 18, 2018, the Company conducted closings on its private placement of securities. As a result of these closings,
the outstanding promissory notes converted into common stock. The redemption feature associated with the promissory notes was
valued on October 18, 2018 using the Black-Scholes model. The change in value of the derivative between July 1, 2018 and the October
18, 2018 was recorded as income. The notes were converted to common stock on October 18, 2018.
The
Company had no financial liabilities accounted for at fair value on a recurring basis as of December 31, 2020 and 2019 and June
30, 2019.
The
following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the
fair value hierarchy:
Year ended
Six months ended
Year ended
(Unaudited)
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Beginning balance
$ -
$ -
$ -
$ 4,194,634
Adoption of ASU 2017-11 – warrants
-
-
-
(59,397 )
Fair value of derivative liabilities for redemption feature of promissory notes payable
-
-
-
-
Change in fair value of derivative liabilities
-
-
-
54,634
Extinguishment of derivative liabilities on conversion of promissory notes.
-
-
-
(4,189,871 )
Ending balance
$ -
$ -
$ -
$ -
The
Company had no financial liabilities classified as level 3 during the year ended December 31, 2020 and the six months ended December
31, 2019.
F- 14
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
NOTE 8 - STOCKHOLDERS’ EQUITY
Common
Stock
During the year ended December 31, 2020 and the six months ended
December 31, 2019 and year ended June 30, 2019, the Company issued 42,475, 42,644, and 24,991 shares of common stock for cashless
exercise of 60,513, 88,751, and 25,004 warrants, respectively. During the year ended December 31, 2020 and the six months ended
December 31, 2019 and year ended June 30, 2019, the Company issued 1,159,989, 656,943, and nil shares of common stock for the exercise
of warrants for proceeds of $8,056,416, $4,447,038 and $nil, respectively.
During the year ended December 31, 2020,
the Company issued 90,204 shares of common stock for cashless exercise of 98,370 options. During the year ended December 31, 2020,
the Company issued 155,558 shares of common stock for the exercise of options for proceeds of $735,514.
During
the six months ended December 31, 2019, the Company issued 61,484 shares of common stock for cashless exercise of 67,578 options.
On
May 15, 2020, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent (“Jefferies”),
pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of the Company’s common stock,
having an aggregate offering price of up to $75,000,000. The Company is not obligated to sell any shares under the agreement.
During the year ended December 31, 2020 the Company issued shares of common stock for net cash proceeds of $19,791,644 under the
agreement.
During
the six months ended December 31, 2019, the Company closed on a private placement of 3,833,334 shares of common stock. The price
per share was $30.00 to the public (with a price to the underwriters of $28.00 per share). The net proceeds from the closing was
$108,621,733. Approximately, $478,000 of legal and professional fees were incurred in relation to the closing. The Company also
closed on a private placement of 117,965 shares for $7.00 per share and net proceeds of $825,749 during the 3 rd calendar
quarter of 2019.
During
the year ended June 30, 2019, the Company closed on private placements of securities pursuant to Unit Purchase Agreements and
Subscription Agreements, each dated as shown below. The price per unit (comprising one common stock and a 5 year warrant to purchase
2.60 or 2.00 of a share of common stock) was $3.60, $5.60 or $6.00. The Company issued an aggregate of 3,975,115 shares of common
stock to investors in these closings, for net proceeds of $17,839,656. Approximately $79,000 of legal costs were incurred that
were not allocated to the individual closings.
Date
of closing
Common
Stock Issued
Warrants
issued
Unit
Price
Net
proceeds
Warrant
exercise price
Warrant
coverage
October
12, 2018
501,027
325,668
$ 3.60
$ 1,630,991
$ 6.00
.65
October 18, 2018
410,084
266,555
$ 3.60
$ 1,287,007
$ 6.00
.65
November 2, 2018
374,864
243,662
$ 3.60
$ 1,215,242
$ 6.00
.65
December 5, 2018
334,694
217,550
$ 3.60
$ 1,083,307
$ 6.00
.65
February 12, 2019
201,389
130,903
$ 3.60
$ 725,000
$ 6.00
.65
March 27, 2019
178,572
89,286
$ 5.60
$ 1,000,000
$ 9.00
.50
May 14, 2019
569,083
284,541
$ 6.00
$ 3,168,865
$ 9.00
.50
June 14, 2019
612,914
306,456
$ 6.00
$ 3,274,331
$ 9.00
.50
June 20, 2019
720,799
360,399
$ 6.00
$ 4,059,050
$ 9.00
.50
June
28, 2019
71,689
35,845
$ 6.00
$ 395,863
$ 9.00
.50
Total
3,975,115
2,260,865
$ 17,839,656
F- 15
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
Approximately $177,000 of the June 28 financing
was in Other Receivable at June 30, 2019 and was received in July, 2019. The October 12, 2018 and October 18, 2018 financings represented
an Equity Financing as defined in the Convertible Promissory Note agreement. As a result of the October 12, 2018 and October 18,
2018 financings, the Company’s outstanding 7% Convertible Promissory Notes and accumulated interest converted into 2,682,917
shares of common stock.
During the year ended December 31, 2020, the
six months ended December 31, 2019, and years ended June 30, 2019, there were no common stock shares issued for issuances of restricted
common stocks, respectively.
Placement Agent Warrants
During the year ended June 30, 2019, the Company
issued an aggregate of 357,396 warrants to the placement agent in connection with the closings. The agent warrants have an exercise
price between $3.96 and $9.00, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date
of issuance. Warrants have a five year term and an aggregate fair value of approximately $1,809,535 calculated using the Black-Scholes
option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rates between 1.74-3.09% (2)
expected life of 5 years, (3) expected volatility between 100.7-103.4%, and (4) zero expected dividends.
Stock-based compensation - options
In December 2014, the Board of Directors
adopted and the shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”),
which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to
purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors.
The Plan allowed for the granting of 5,152,942 options or stock awards.
Stock options are exercisable generally for a period of 10 years
from the date of grant and generally vest over four years. As of December 31, 2020, 1,247,205 shares were available for future
grants under the Plan.
The Company uses the simplified method for
share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing
model.
During the year ended December 31, 2020,
the Company awarded a total of 1,000,000 options to employees with exercise prices ranging from $28.00- $45.61 and a 10-year term
vesting over 4-year period. The options have an aggregate fair value of $32.4 million calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.36%-0.83% (2) expected life of
6.25 years, (3) expected volatility of 101%-108%, and (4) zero expected dividends.
During the year ended December 31, 2020,
the Company recognized additional compensation expense of approximately $1,500,000 related to acceleration of vesting and a nominal
amount related to the modification of certain options in connection with the separation and settlement agreement with Dr. Ottavio
Vitolo (see note 11).
During the year ended December 31, 2020,
the Company recognized compensation expense of approximately $484,000 related to the extended period of time to allow for some
options to vest under the separation and settlement agreement with Dr. Thomas Wessel. This was considered a Type III modification
and as a result the total expense of $1.8 million previously recognized was reversed as the options would not have vested prior
to the modification (see note 11).
On December 19, 2019, the Company granted employees
options to purchase a total of 1,295,000 shares of common stock. The options have a ten-year term and have an exercise price of
$43.47 and vest over 4 years. The options have an aggregate fair value of $46,904,043 calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.79% (2) expected life of 6.25 years,
(3) expected volatility of 108.2%, and (4) zero expected dividends.
On December 19, 2019, the Company granted a
consultant options to purchase a total of 10,000 shares of common stock. The options have a ten-year term and have an exercise
price of $43.47 and vest immediately. The options have an aggregate fair value of $338,992 calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.73% (2) expected life of 5 years,
(3) expected volatility of 107.4%, and (4) zero expected dividends.
On April 1, 2019, the Company granted various
employees options to purchase a total of 37,500 shares of common stock. The options have a ten-year term and have an exercise price
of $7.04 and vest over 4 years. The options have an aggregate fair value of $214,000 calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.37% (2) expected life of 6.25 years,
(3) expected volatility of 101.5%, and (4) zero expected dividends.
On December 20, 2018, the Company granted various employees options
to purchase a total of 675,000 shares of common stock. The options have a ten-year term and have an exercise price of $4.60 and
vest over 4 years. The options have an aggregate fair value of $2,500,000 calculated using the Black-Scholes option-pricing model.
Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3)
expected volatility of 102.3%, and (4) zero expected dividends.
F- 16
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
A
summary of the changes in options outstanding for the periods ended December 31, 2020 and 2019, and June 30, 2019 is as follows:
Number of Shares
Weighted Average Exercise Price Per Share
Weighted Average Remaining Contractual Term
(Years)
Aggregate Intrinsic
Value
Outstanding and expected to vest at June 30, 2018
767,220
$ 5.80
8.8
$ 511,000
Granted
712,500
4.73
9.5
-
Forfeited
(6,406 )
-
-
-
Outstanding and expected to vest at June 30, 2019
1,473,314
$ 5.18
8.6
$ 4,668,153
Granted
2,205,000
29.32
9.8
-
Exercised
(62,712 )
-
-
$ -
Outstanding and expected to vest at December 31, 2019
3,615,602
$ 19.96
9.2
$ 74,837,043
Granted
1,000,000
39.50
9.3
-
Exercised
(253,927 )
-
-
-
Forfeited
(455,938 )
-
-
-
Outstanding and expected to vest at December 31, 2020
3,905,737
$ 24.32
8.4
$ 48,952,339
Options exercisable at December 31, 2020
1,241,359
$ 16.73
7.7
$ 22,960,117
At December 31, 2020, the Company has unrecognized stock-based
compensation expense of approximately $53,502,000 related to unvested stock options over the weighted average remaining service
period of 3.04 years. The weighted average fair value of options granted during the years ended December 31, 2020 and 2019, the
six months ended December 31, 2019 and the year ended June 30, 2019 was approximately $32.45, $24.00 (unaudited), $24.31 and $3.84
per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions:
(Unaudited)
Years Ended
Years Ended
Six Months ended
Year ended
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Risk free interest rate
0.36 to 0.83
%
1.73 to 2.37
%
1.73 to 1.79
%
2.37 to 2.69
%
Dividend yield
0
%
0
%
0
%
0
%
Volatility
101-108
%
101.5-108
%
107.4-108.2
%
101.5-102.3
%
Expected term (in years)
6.25
5 to 6.25
5 to 6.25
6.25
F- 17
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
Warrants
A summary of the changes in outstanding warrants during the
year ended December 31, 2020 and six months ended December 31. 2019, and year ended June 30, 2019 is as follows:
Number of Shares
Weighted Average Exercise Price Per Share
Outstanding at June 30, 2018
2,453,757
$
15.845
Issued
2,691,123
$
7.10
Exercised
(25,004
)
$
0.004
Forfeited/Expired
(689,894
)
$
18.94
Outstanding at June 30, 2019
4,429,982
$
7.12
Issued
21,250
$
10.25
Exercised
(740,694
)
$
7.80
Forfeited/Expired
(63,666
)
$
13.89
Outstanding at December 31, 2019
3,646,872
$
6.83
Issued
250,000
$
33.32
Exercised
(1,211,199
)
$
7.27
Forfeited/Expired
(15,040
)
$
16.80
Outstanding at December 31, 2020
2,670,633
$
9.11
Warrants exercisable at December 31, 2020
2,646,257
$
9.16
Included
in the warrants outstanding at June 30, 2018 are 643,643 warrants that expired in the year ended June 30, 2019. These warrants
had an exercise price that was subject to downward adjustment on the sale of equity at prices below their original exercise price.
On December 16, 2020, the Company granted
20,000 warrants to a consultant with an exercise price of $34.87, a 5-year term and vesting over 4 years. The warrants have an
aggregated fair value of $479 thousand using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate of 0.37% (2) expected life of 3.75 years, (3) expected volatility of 105%, and (4) zero expected
dividends
On December 16, 2020, the Company granted
108,000 warrants to consultants with an exercise price of $34.87, a 5-year term and vesting based on future events. The warrants
have an aggregated fair value of $2.86 million that was calculated using the Black-Scholes option-pricing model. Variables used
in the Black-Scholes option-pricing model include: (1) discount rate of 0.37% (2) expected life of 5 years, (3) expected volatility
of 105%, and (4) zero expected dividends
On April 27, 2020, the Company granted
2,000 warrants to a consultant with an exercise price of $37.67, a 5-year term and immediate vesting. The warrants have an aggregated
fair value of $48 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate of 0.27% (2) expected life of 2.5 years, (3) expected volatility of 116%, and (4)
zero expected dividends.
On April 1, 2020, the Company granted 120,000
warrants to consultants with an exercise price of $31.59, a 5-year term and immediate vesting. The warrants have an aggregated
fair value of $2.5 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate of 0.26% (2) expected life of 2.5 years, (3) expected volatility of 118%, and (4)
zero expected dividends.
On October 8, 2019, the Company granted
15,000 warrants to a contractor with an exercise price of $10.85, non-cancellable term and immediate vesting. The warrants have
an aggregated fair value of $121,252 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate of 1.36% (2) expected life of 5 years, (3) expected volatility of 100%, and (4)
zero expected dividends.
F- 18
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
On August 1, 2019, the Company granted
6,250 warrants to a contractor with an exercise price of $8.80, a 10-year term and immediate vesting. The warrants have an aggregated
fair value of $41,386 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate of 1.68% (2) expected life of 5 years, (3) expected volatility of 101.1%, and (4) zero expected
dividends.
On March 9, 2019, the Company granted 17,857
warrants to a consultant with an exercise price of $7.00, a 5-year term and immediate vesting. The warrants have an aggregated
fair value of $95,131 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate of 2.42% (2) expected life of 5 years, (3) expected volatility of 102.0%, and (4) zero expected
dividends.
On January 1, 2019, the Company granted
30,000 warrants to a contractor with an exercise price of $4.60, a 10-year term and quarterly vesting over four years vesting.
The warrants have an aggregated fair value of $112,183 that was calculated using the Black-Scholes option-pricing model. Variables
used in the Black-Scholes option-pricing model include: (1) discount rate of 2.49% (2) expected life of 6.25 years, (3) expected
volatility of 102.0%, and (4) zero expected dividends.
On December 20, 2018, the Company granted
25,000 warrants to a contractor with an exercise price of $4.60, a 10-year term and immediate vesting. The warrants have an aggregated
fair value of $93,762 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected
dividends.
During the year ended June 30, 2019, the
Company issued an aggregate of 2,260,860 warrants to investors in connection with private placements, with a fair value of approximately
$11,420,300. The exercise price ranges from $6.00 to $9.00, vested upon issuance, are non-cancellable and expire on the fifth anniversary
from issuance. Variables used in the Black-Scholes option-pricing model include: (1) discount rates of 1.74-3.09% (2) expected
life of 5 years, (3) expected volatility of 100.7-103.4%, and (4) zero expected dividends.
At December 31, 2020, the Company had $3.4
million of unrecognized stock-based compensation expense related to outstanding warrants. At December 31, 2020, the aggregate intrinsic
value of warrants vested and outstanding was $61.2 million.
Stock-based
compensation by class of expense
The
following summarizes the components of stock-based compensation expense which includes common stock, stock options, warrants and
restricted stock in the consolidated statements of operations (rounded to nearest $00):
(Unaudited)
Year
Ended
Year
Ended
Six Months ended
Year ended
December 31,
December 31,
December 31,
June 30,
2020
2019
2019
2019
Research and development
$
4,038,500
$
360,900
$
174,500
$
215,900
General and administrative
16,738,800
2,804,300
2,192,500
998,100
Total
$
20,777,300
$
3,165,200
$
2,367,000
$
1,214,000
NOTE 9 - INCOME TAXES
No
provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods
presented and has recorded a valuation allowance against its deferred tax assets.
F- 19
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
No provision or benefit for federal or
state income taxes has been recorded because the Company has incurred net losses for all periods presented and has recorded a valuation
allowance against its deferred tax assets.
The
components of the Company’s deferred tax assets are as follows at:
December 31,
2020
December 31,
2019
June 30,
2019
Deferred tax assets:
Federal net operating loss
$ 15,227,000
$ 13,022,000
$ 13,555,000
State net operating loss
9,361,000
7,912,000
8,252,000
Research and development tax credits
3,407,000
1,499,000
1,230,000
Capitalized R&D
14,387,000
3,168,000
-
Nonqualified Stock Options
7,352,000
172,000
-
Accruals
645,000
133,000
206,000
Other
41,000
45,000
46,000
Less: valuation allowance
(50,420,000 )
(25,951,000 )
(23,289,000 )
Total
$ -
$ -
$ -
On March 27, 2020, the Coronavirus
Aid Relief and Economic Security (“CARES”) Act was signed into law. The Act contains several new or changed
income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest
expense, class life changes to qualified improvements (in general, from 39 years to 15 years) and the ability to carry back net
operating losses (“NOLs”) incurred from tax years 2018 through 2020 up to the five preceding tax years. Most
of these provisions are either not applicable or have no material effect on the Company.
The Company has maintained a full valuation
allowance against its deferred tax assets at December 31, 2020 and 2019, and June 30, 2019. A valuation allowance is required to
be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since
the Company cannot be assured of realizing the net deferred tax asset, a full valuation allowance has been provided. The valuation
allowance increased/(decreased) for the year ended December 31, 2020, the six months December 31, 2019 and the year ended June
30, 2019, by approximately $24,469,000, $2,662,000, and $4,357,000, respectively. Deferred tax asset for net operating loss carryforwards
at December 31, 2020 was adjusted with the corresponding offset to valuation allowance.
At December 31, 2020, the Company had federal, New York State
and New York City net operating loss (NOL) carryforwards of approximately $72,507,000, $68,854,000 and $68,470,000 respectively,
which begin expiring in 2027, 2032 and 2032 respectively. Approximately $27,037,000 federal NOL can be carried forward indefinitely
but it is limited to 80% of future taxable income. The Company also has federal research and development tax credit carryforwards
of approximately $3,407,000 that will begin to expire in 2028. The Company's ability to use its NOL carryforwards may be limited
if it experiences an "ownership change" as defined in Section 382 ("Section 382") of the Internal Revenue Code
of 1986, as amended. An ownership change generally occurs if certain stockholders increase their aggregate percentage ownership
of a corporation's stock by more than 50 percentage points over their lowest percentage ownership at any time during the testing
period, which is generally the three-year period preceding any potential ownership change. The Company has not completed an analysis
to determine whether any such limitations have been triggered as of December 31, 2020.
A
reconciliation of the statutory tax rate to the effective tax rate is as follows:
Year Ended
December 31, 2020
(Unaudited)
Year Ended
December 31, 2019
Six Months Ended
December 31,
2019
Year Ended
June 30,
2019
Statutory federal income tax rate
21.00 %
21.00 %
21 %
21 %
State (net of federal benefit)
15.50 %
16.21 %
11.96 %
9.5 %
Non-deductible expenses
0.42 %
(4.24 )%
(5.75 )%
(6.3 )%
R&D Credit
3.21 %
3.02 %
- %
- %
Other
1.01 %
1.08 %
5.27 %
1 %
Change in valuation allowance
(41.15 )%
(37.07 )%
(32.48 )%
(25.2 )%
Effective income tax rate
0 %
0 %
0 %
0 %
The
Company does not have any uncertain tax positions at December 31, 2020, December 31, 2019 and June 30, 2019 that would affect
its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the
next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and
state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable,
the Company will recognize interest and penalties as part of income tax expense.
F- 20
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
NOTE 10 - COMMITMENTS AND CONTINGENCIES
License
Agreements
Wonpung
On
August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung Mulsan Co, a shareholder
of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company
is currently developing and a right of first refusal (ROFR) for up to an additional five drugs that the Company may develop in
the future as defined in more detail in the license agreement.
The
Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed
products it is currently developing. The licensing terms for the ROFR products are subject to future negotiations and binding
arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing
or on the date of commercial availability of a generic product to such licensed product in the licensed territory.
Third
Party Licensor
Based upon a prior acquisition, the Company
assumed an obligation to pay a third party (Dr. Charles E. Inturrisi and Dr. Paolo Manfredi - see below): (A) royalty payments
up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty
payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties
received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or
$2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the
first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.
As of December 31, 2020, the Company has not generated any revenue related to this license agreement.
Inturrisi
/ Manfredi
In January 2018, we entered into an
Intellectual Property Assignment Agreement (the Assignment Agreement) and License Agreement (the “License Agreement”
and together with the Assignment Agreement, the Agreements) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively,
the Licensor). Pursuant to the Agreements, Relmada assigned its existing rights, including patents and patent applications, to
esmethadone in the context of psychiatric use (the Existing Invention) to Licensor. Licensor then granted Relmada under the License
Agreement a perpetual, worldwide, and exclusive license to commercialize the Existing Invention and certain further inventions
regarding esmethadone in the context of other indications such as those contemplated above. In consideration of the rights granted
to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally,
Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial
sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of
the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered
royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products
covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%,
and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.
Leases and
Subleases
As of January 1, 2019, the Company changed
its corporate headquarters to 880 Third Avenue, 12th Floor, New York, New York 10022 pursuant to a lease agreement with an initial
monthly rent of $7,500. The lease period was for one year. The lease agreement expired on December 31, 2019 and was renewed for
calendar years 2020 and 2021. As the Company’s leases consist of one lease for their corporate headquarters, which is for
a period of 12 months or less. The Company has elected the practical expedient and recognizes rent expense evenly over the 12 months.
The Company incurred rent expense of approximately
$165,900, 93,900, $47,100, and $114,800 for the year ended December 31, 2020 and December 31, 2019 (unaudited), the six months
ended December 31, 2019 and year ended June 30, 2019, respectively.
In June 2015, the Company entered into
an Agreement of Lease (the Lease) for office space located at 275 Madison Avenue, 7th Floor, New York, New York 10016, its former
corporate headquarter, with a third party. On March 10, 2016 and effective as of January 1, 2016, the Company entered into an Office
Space License Agreement (the License) with Actinium Pharmaceuticals, Inc. (Actinium), with whom the Company shared two common board
members until June 6, 2017, for the office space. The term of the License was three years from the effective date, with an automatic
renewal provision. The cost of the License was approximately $16,600 per month for Actinium, subject to customary escalations and
adjustments. The Company recorded the license fees as other income in the consolidated statements of operations.
On June 8, 2017, the Company entered into
an Amended and Restated License Agreement with Actinium. Pursuant to the terms of the agreement, Actinium will continue to license
the furniture, fixtures, equipment and tenant improvements located in the office (FFE) for a license fee of $7,529 per month until
December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914,
less any previously paid license fees. The license of FFE qualifies as a sales-type lease. On June 8, 2017 the Company derecognized
the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38%
and recognized loss on sales-type lease of fixed assets of $96,403. As of December 31, 2020 and 2019, and June 30, 2019, the balance
of unearned interest income was approximately $14,900, $32,100 and 43,000, respectively.
F- 21
Relmada
Therapeutics, Inc.
Notes
to Consolidated Financial Statements
The future minimum lease payments to be
received under the lease for each year as of December 31, 2020 are as follows:
2021
$ 90,348
2022
90,348
Total
$ 180,696
Legal
From
time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business.
Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence.
Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome
would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial
condition, operating results, or cash flows.
Lawsuit
Brought by Former Officer
In
2014, Relmada dismissed with prejudice its lawsuit against Najib Babul, which had sought to compel Dr. Babul, Relmada’s
former President, to account for questionable expenditures of Relmada funds made while Babul controlled the Company. Relmada’s
decision to end its claims was informed by the fact that Babul came forward with plausible explanations for some of the expenditures,
and the fact that, because Babul was a former officer and director of Relmada being sued for his conduct in office, the Company
was required to advance his expenses of the litigation; hence, Relmada was paying all the lawyers and consultants on both sides
of the dispute. Relmada also agreed to reinstate certain stock purchase warrants in Babul’s name, which had been cancelled
during the pendency of the litigation, and offered Babul the right to exchange his shares in Relmada Therapeutics, Inc. (a Delaware
corporation and subsidiary of the Company) for shares in the Company.
Babul
has brought a second lawsuit against Relmada. Ruling on Relmada’s Motion to Dismiss, the United States District Court for
the Eastern District of Pennsylvania dismissed Babul’s claims for breach of contract and intentional infliction of emotional
distress, and left intact his claims for defamation, and wrongful use of civil process.
On
February 6, 2019, the Company entered into a settlement agreement in which Babul relinquished his 303,392 shares in Relmada, signed
a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31,
2019, June 30, 2019, September 30, 2019 and December 31, 2019.
For
accounting purposes, no fair value was attributed to the consulting agreement. The Company recorded a loss on settlement of $1,105,590
included in the general and administrative expenses for the year ended June 30, 2019. The loss represents the total cash payments
of $1,500,000 less the fair value of the shares relinquished of $394,410.
Lawsuit Brought by Current Employee
On July 15, 2020, an employee of the Company filed a Complaint alleging
unequal pay based on gender and other employment-based claims. The Company intends to defend the lawsuit vigorously, it is currently in
discovery and the ultimate outcome is not known.
NOTE 11 - RELATED PARTY TRANSACTIONS
Effective March 6, 2020, Dr. Vitolo entered
into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr.
Vitolo severance of $200,000 in accordance with his employment contract. In addition, Dr. Vitolo’s options granted under
the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until September 6, 2020. Dr. Vitolo shall have
until March 6, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his
vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company
agreed to pay accrued and unpaid salary, vacation time and attorney’s fees totaling approximately $45,000.
Effective December 31, 2020, Dr. Wessel
entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed
to pay Dr. Wessel severance of $237,500 in accordance with his employment contract. In addition, Dr. Wessel’s options granted
under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until June 30, 2021. Dr. Wessel shall have
until December 31, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise
his vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company
agreed to pay accrued vacation time totaling approximately $28,940.
F- 22
NOTE 12 - OTHER POSTRETIREMENT
BENEFIT PLAN
Relmada participates
in a multiemployer 401(k) plan that permits eligible employees to contribute funds on a pretax basis subject to maximum allowed
under federal tax provisions. The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions
that exceed 3% but do not exceed 5%.
The employees
choose an amount from various investment options for both their contributions and the Company’s matching contribution. The
Company’s contribution expense was $90,692, $20,081, $10,261, and $18,853 for the year ended December 31, 2020 and December
31, 2019 (unaudited), the six months ended December 31, 2019 and year ended June 30, 2019, respectively.
NOTE
13 - SUBSEQUENT EVENTS
From January 1 st through March
15, 2021, 271,366 warrants with an average exercise price of $5.31 were exercised, for net proceeds of $1,441,382.
From January 1 st through March
15, 2021, 141,625 options with an average exercise price of $3.30 were exercised, for net proceeds of $467,772.
On January 7, 2021, the Company awarded
a total of 1,490,000 options to employees and board of directors at an exercise price of $33.43 and a 10-year term vesting over
a four-year period. The grants to the employees are 50% based on a four year vesting term and the other 50% are based on milestones
achieved.
On January 7, 2021, the Company awarded
Drs. Manfredi and Pappagallo, Acting CSO and Acting CMO, respectively, 200,000 warrants each, with an exercise price of $33.43
per share and a duration of 10 years from 1/7/2021. Half of each award shall vest 6.25% per quarter starting 4/7/21. The other
half of each award shall vest 25% on 1/7/22, then 6.25% per quarter, and shall be subject to the same forfeiture for contingencies
as the management options.
On February 3, 2021, the Company awarded
a total of 25,000 options to a new employee with an exercise price of $34.47 and a 10-year term vesting over a four-year period.
The Company’s lease agreement at
880 Third Avenue expired on December 31, 2020 and has been renewed for calendar year 2021. Included in this lease is additional
office space on the 10 th floor along with the existing space on the 5 th floor for an average monthly cost
of approximately $8,730.
F- 23
Exhibits
Certain
of the agreements filed as exhibits to this Report contain representations and warranties by the parties to the agreements that
have been made solely for the benefit of the parties to the agreement. These representations and warranties:
● may
have been qualified by disclosures that were made to the other parties in connection
with the negotiation of the agreements, which disclosures are not necessarily reflected
in the agreements;
● may
apply standards of materiality that differ from those of a reasonable investor; and
● were
made only as of specified dates contained in the agreements and are subject to subsequent
developments and changed circumstances.
Accordingly,
these representations and warranties may not describe the actual state of affairs as of the date that these representations and
warranties were made or at any other time. Investors should not rely on them as statements of fact.
Exhibit
Number
Description
2.1
Share
Exchange Agreement, dated May 20, 2014, by and among Camp Nine, Inc., Relmada Therapeutics, Inc., and the stockholders of
Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Relmada’s Form 8-K filed with the SEC on May
27, 2014).
3.1
(i)
Articles of Incorporation of Camp Nine, Inc. (incorporated by reference to Exhibit 3.1 of Relmada’s Registration Statement
on Form S-1 filed with the SEC on November 13, 2012).
(ii)
Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Relmada’s Report on Form
8-K filed with the SEC on May 19, 2014).
(iii)
Nevada Certificate of Amendment to Articles of Incorporation of Camp Nine, Inc., effective May 30, 2014 (incorporated by reference
to Exhibit 3.1 of Relmada’s Form 8-K filed with the SEC on June 2, 2014).
(iv)
Nevada Certificate of Amendment to Articles of Incorporation of Camp Nine, Inc., effective July 8, 2014 (incorporated by reference
to Exhibit 3.1 of Relmada’s Form 8-K filed with the SEC on July 14, 2014).
3.2
(i)
Amended and Restated Certificate of Incorporation of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.2(i)
of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
(ii)
Amendment effective April 19, 2013 to Certificate of Incorporation of Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 3.2(ii) of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
(iii)
Certificate of Amendment to Articles of Incorporation of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit
3.1 of Relmada’s Form 10-Q filed with the SEC on February 13, 2015).
(iv)
Certificate of Change of Relmada Therapeutics, Inc. dated August 4, 2015 (incorporated by reference to Exhibit 3.1 of Relmada’s
Form 8-K filed with the SEC on August 10, 2015).
(v)
Certificate of Change of Relmada Therapeutics, Inc. dated September 26, 2019 (incorporated by reference to Exhibit 3.1 of
Relmada’s Form 8-K filed with the SEC on September 27, 2019).
3.3
Second
Amended and Restated Bylaws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 of Relmada’s Form
8-K filed with the SEC on November 25, 2015).
4.1
Form
of Warrants to Purchase Common Stock issued in 2012 and 2013 in connection with Relmada Therapeutics, Inc. Series A Preferred
Stock (incorporated by reference to Exhibit 4.1 of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
4.2
Form
of Warrants to Purchase Common Stock issued in 2012 and 2013 in connection with Relmada Therapeutics, Inc. 8% Senior Subordinated
Promissory Notes (incorporated by reference to Exhibit 4.2 of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
4.3
Form
of B Warrant dated May __, 2014 issued to investors by Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.4
of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
4.4
Form
of B Warrant dated June 10, 2014 issued to investors by Camp Nine, Inc. (incorporated by reference to Exhibit 4.2 of Relmada’s
Form 8-K filed with the SEC on June 16, 2014).
40
Exhibit
Number
Description
4.5
Form
of Convertible Promissory Note (incorporated by reference to Exhibit 4.1 of Relmada’s Form 10-Q filed with the SEC on
February 12, 2018).
4.6
Form
of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of Relmada’s Form 10-Q filed with the
SEC on February 12, 2018).
4.7
Form
of 2018 Warrant (incorporated by reference to Exhibit 4.1 of Relmada’s Form 10-Q filed with the SEC on November 13,
2018).
4.8
Form
of 2019 Warrant (incorporated by reference to Exhibit 4.1 of Relmada’s Form 10-Q filed with the SEC on May 15, 2019).
4.9
Description of Securities (incorporated by reference to the description of the Company’s common stock, par value $0.001 per share, under the heading “Description of Securities We May Offer—Authorized Capital Stock; Issued and Outstanding Capital Stock,” “—Common Stock,” “—Forum for Adjudication of Disputes, “—Anti-takeover Effects of Our Articles of Incorporation and By-laws, and “—Anti-takeover Effects of Nevada Law” in the Company’s Registration Statement on Form S-3 (File No. 333-245054), filed with the Securities and Exchange Commission on August 12, 2020)
10.1
Agreement
and Plan of Merger dated as of December 31, 2013 between Relmada Therapeutics, Inc. and Medeor, Inc. (incorporated by reference
to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
10.2
Non-Disclosure,
Assignment of Inventions, Non-Solicitation and Non-Compete Agreement dated as of April 18, 2012 between Sergio Traversa and
Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on May
27, 2014).
10.6
Indemnification
Agreement dated July 10, 2012 between Relmada Therapeutics, Inc. and Sergio Traversa (incorporated by reference to Exhibit
10.10 of Relmada’s Form 8-K filed with the SEC on May 27, 2014).
10.7
2012
Relmada Therapeutics, Inc. Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.11 of Relmada’s
Form 8-K filed with the SEC on May 27, 2014).
10.11
2014
Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.14 of Relmada’s Form S-1/A filed with
the SEC on December 9, 2014)
10.13
Director
Agreement, dated July 14, 2015, by and between Charles J. Casamento and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on July 16, 2015)
10.14
Director
Indemnity Agreement, dated July 14, 2015, by and between Charles J. Casamento and Relmada Therapeutics, Inc. (incorporated
by reference to Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on July 16, 2015)
10.15
Amended
2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of Relmada’s Form 8-K filed with
the SEC on August 7, 2015).
10.16
Form
of Indemnification Agreement (incorporated by reference to Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on
August 7, 2015).
10.17
Amended
and Restated Employment Agreement, dated August 5, 2015, by and between Relmada Therapeutics, Inc. and Sergio Traversa (incorporated
by reference to Exhibit 10.4 of Relmada’s Form 8-K filed with the SEC on August 7, 2015).
41
Exhibit
Number
Description
10.21
Assignment
and Consent Agreement, dated June 6, 2017, among 275 Madison Avenue RPW 1 LLC, 275 Madison Avenue RPW 2, LLC, Actinium Pharmaceuticals,
Inc. and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.21 of Relmada’s Form 10-K filed with the
SEC on September 28, 2017).
10.22
Lease
Agreement, dated May 2, 2017, between Relmada Therapeutics, Inc. and Regus Management Group, LLC. (incorporated by reference
to Exhibit 10.22 of Relmada’s Form 10-K filed with the SEC on September 28, 2017).
10.23
Amended
and Restated License Agreement, dated June 8, 2017, between Actinium Pharmaceuticals, Inc. and Relmada Therapeutics, Inc.
(incorporated by reference to Exhibit 10.23 of Relmada’s Form 10-K filed with the SEC on September 28, 2017).
10.27
License
Agreement, dated January 16, 2018, between Relmada Therapeutics, Inc. Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (incorporated
by reference to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on January 19, 2018).
10.28
Intellectual
Property Assignment Agreement, dated January 16, 2018, between Relmada Therapeutics, Inc. Dr. Charles E. Inturrisi and Dr.
Paolo Manfredi (incorporated by reference to Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on January 19, 2018).
10.29
Form
of Note and Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 of Relmada’s Form 10-Q filed with
the SEC on February 12, 2018).
10.30
Offer
Letter, Dated March 28, 2018, between Relmada Therapeutics, Inc. and Ottavio Vitolo (incorporated by reference to Exhibit
10.1 of Relmada’s Form 10-Q filed with the SEC on May 14, 2018).
10.31
Indemnification
Agreement, dated April 2, 2018, between Relmada Therapeutics, Inc. and Ottavio Vitolo (incorporated by reference to Exhibit
10.2 of Relmada’s Form 10-Q filed with the SEC on May 14, 2018).
10.32
Third
Amendment to the 2014 Stock Option and Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 of Relmada’s
Form 10-Q filed with the SEC on May 14, 2018).
10.33
Form
of Unit Purchase Agreement among Relmada Therapeutics, Inc. and certain accredited investors (incorporated by reference to
Exhibit 10.1 of Relmada’s Form 10-Q filed with the SEC on November 13, 2018).
42
Exhibit
Number
Description
10.36
Lease
Agreement, effective January 1, 2019, between Relmada Therapeutics, Inc. and 880 Third Avenue Tenant LLC (incorporated by
reference to Exhibit 10.1 of Relmada’s Form 10-Q filed with the SEC on February 13, 2019).
10.37
Settlement
Agreement, dated February 6, 2019, among Najib Babul, Laidlaw & Company (UK) Ltd., Sandesh Seth, and Sergio Traversa (incorporated
by reference to Exhibit 10.2 of Relmada’s Form 10-Q filed with the SEC on February 13, 2019).
10.38
Consulting
Agreement, effective March 25, 2019, between Relmada Therapeutics, Inc. and Najib Babul (incorporated by reference to Exhibit
10.3 of Relmada’s Form 10-Q filed with the SEC on February 13, 2019).
10.39
Amendment
No. 4 to the Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, as amended (incorporated by reference
to Exhibit 10.1 of Relmada’s Form 10-Q filed with the SEC on May 15, 2019).
10.43
Consulting
Agreement, dated July 29, 2019, by and between Charles S. Ence and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on July 29, 2019).
10.44
Indemnification
Agreement, dated July 29, 2019, by and between Charles S. Ence and Relmada Therapeutics, Inc. (incorporated by reference to
Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on July 29, 2019).
10.45
Confidential
Information and Invention Assignment Agreement, dated July 29, 2019, by and between Charles S. Ence and Relmada Therapeutics,
Inc. (incorporated by reference to Exhibit 10.3 of Relmada’s Form 8-K filed with the SEC on July 29, 2019).
10.46
Form
of Share Purchase Agreement, dated September 23, 2019 and September 26, 2019, among Relmada Therapeutics, Inc. and certain
accredited investors named therein (incorporated by reference to Exhibit 10.4 of Relmada’s Form 10-Q filed with the
SEC on November 13, 2019).
10.47
Form
of Registration Rights Agreement, dated September 23, 2019 and September 26, 2019, among Relmada Therapeutics, Inc. and certain
accredited investors named therein (incorporated by reference to Exhibit 10.5 of Relmada’s Form 10-Q filed with the
SEC on November 13, 2019).
10.48
Amended
and Restated Unit Purchase Agreement dated November 27, 2019, between Relmada Therapeutics, Inc., and certain accredited investors
(incorporated by reference to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on December 3, 2019).
10.49
Amendment
No.1 To License Agreement dated December 2, 2019, to the License Agreement dated January 16, 2018 between Relmada
Therapeutics, Inc., and Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (incorporated by reference to Exhibit 10.2 of Relmada’s
Form 8-K filed with the SEC on December 3, 2019).
10.50
Director
Agreement, effective December 19, 2019, by and between Eric Schmidt and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on December 26, 2019).
43
Exhibit
Number
Description
10.51
Indemnity
Agreement, effective December 19, 2019, by and between Eric Schmidt and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on December 26, 2019).
10.52
Director
Agreement, effective December 19, 2019, by and between John Glasspool and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.3 of Relmada’s Form 8-K filed with the SEC on December 26, 2019).
10.53
Indemnity
Agreement, effective December 19, 2019, by and between John Glasspool and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.4 of Relmada’s Form 8-K filed with the SEC on December 26, 2019).
10.54
Employment
Agreement, dated January 9, 2020, by and between Maged Shenouda and Relmada Therapeutics, Inc. (incorporated by reference
to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on January 10, 2020).
10.55
Employment
Agreement, dated January 9, 2020, by and between Charles Ence and Relmada Therapeutics, Inc. (incorporated by reference to
Exhibit 10.2 of Relmada’s Form 8-K filed with the SEC on January 10, 2020).
10.56
Amended
and Restated Employment Agreement, dated January 9, 2020, by and between Sergio Traversa and Relmada Therapeutics, Inc. (incorporated
by reference to Exhibit 10.3 of Relmada’s Form 8-K filed with the SEC on January 10, 2020).
10.57
Amendment
No. 5 to Stock Option and Equity incentive Plan (incorporated by reference to Exhibit 10.1 of Relmada’s Form 8-K filed
with the SEC on March 9, 2020).
10.58
Employment
Agreement, dated March 7, 2020, by and between Thomas Wessel and Relmada Therapeutics, Inc. (incorporated by reference to
Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on March 12, 2020).
10.59
Severance and Separation Agreement, dated April 1, 2020, by and between Ottavio Vitolo and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.6 of Relmada’s Form 10-Q filed with the SEC on May 15, 2020).
10.60
Open Market Sale Agreement SM dated as of May 15, 2020 by and between Relmada Therapeutics, Inc. and Jefferies LLC. (incorporated by reference to Exhibit 10.7 of Relmada’s Form 10-Q filed with the SEC on May 15, 2020).
10.61*
Relmada Therapeutics, Inc., 2021 Equity Incentive Plan
21.1
List
of Subsidiaries (incorporated by reference to Exhibit 21.1 of Relmada’s Form 10-K filed with the SEC on September 9,
2014).
23.1
Consent of Marcum LLP
31.1*
Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*
Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*
Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*
Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS *
XBRL Instance Document
101.SCH *
XBRL Taxonomy Schema
101.CAL *
XBRL Taxonomy Calculation
Linkbase
101.DEF *
XBRL Taxonomy Definition
Linkbase
101.LAB*
XBRL Taxonomy Label
Linkbase
101.PRE *
XBRL Taxonomy Presentation
Linkbase
* Filed
herewith
44
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf
of the Registrant.
Dated: March 24, 2021
RELMADA THERAPEUTICS, INC.
By:
/s/
Sergio Traversa
Sergio Traversa
Chief
Executive Officer
(Duly
Authorized Officer and
Principal
Executive Officer)
By:
/s/
Maged Shenouda
Maged Shenouda
Chief
Financial Officer
(Duly
Authorized Officer and
(Principal
Financial and Accounting Officer)
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf
of the Registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/
Sergio Traversa
Chief Executive
Officer,
March
24, 2021
Sergio Traversa
and Director
/s/
Maged Shenouda
Chief Financial Officer
March 24, 2021
Maged Shenouda
/s/
Charles J. Casamento
Chairman of the Board
March 24, 2021
Charles J. Casamento
/s/
Paul Kelly
Director
March 24, 2021
Paul Kelly
/s/
Eric Schmidt
Director
March 24, 2021
Eric Schmidt
/s/
John Glasspool
Director
March 24, 2021
John Glasspool
45
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.